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The Progress and Prospect of Zeolitic Imidazolate
Frameworks in Cancer Therapy, Antibacterial Activity,
and Biomineralization
Aziz Maleki,* Mohammad-Ali Shahbazi, Vajiheh Alinezhad, and Hélder A. Santos*
The progressive development of zeolitic imidazolate frameworks (ZIFs), as a
subfamily of metal-organic frameworks (MOFs), and their unique features,
including tunable pore size, large surface area, high thermal stability, and
biodegradability/biocompatibility, have made them attractive in the field of
biomedicine, especially for drug delivery and biomineralization applications.
The high porosity of ZIFs gives them the opportunity for encapsulating a high
amount of therapeutic drugs, proteins, imaging cargos, or a combination of
them to construct advanced multifunctional drug delivery systems (DDSs)
with combined therapeutic and imaging capabilities. This review summarizes
recent strategies on the design and fabrication of ZIF-based nansystems and
their exploration in the biomedical field. First, recent developments for the
adjustment of particle size, functionality, and morphology of ZIFs are
discussed, which are important for achieving optimized therapeutic/
theranostic nanosystems. Second, recent trends on the application of ZIF
nanocarriers for the loading of diverse cargos, including anticancer medicines,
antibiotic drugs, enzymes, proteins, photosensitizers, as well as imaging and
photothermal agents, are investigated in order to understand how
multifunctional DDSs can be designed based on the ZIF nanoparticles to treat
different diseases, such as cancer and infection. Finally, prospects on the
future research direction and applications of ZIF-based nanomedicines are
discussed.
1. Introduction
Unprecedented advantages of nanomaterials have introduced
them in recent decades as a potent platform in biomedicine,
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which can play a vital role in the therapy and
diagnosis of many diseases.[1] For example,
biomedical applications of porous mate-
rials, such as metal-organic frameworks
(MOFs) have extensively been explored with
the aim of fabricating novel drug formula-
tions with better biological performance as
compared to conventional medicines.[2–4]
Zeolitic imidazolate frameworks (ZIFs) are
a subfamily of MOFs with desirable prop-
erties, including high porosity, excellent
thermal and mechanical stability, tunable
surface properties, and exceptional chem-
ical stability as a result of high resistance
to alkaline water and organic solvents.[5]
These features have made ZIFs excellent
candidates for many applications, such
as gas capture,[6] separations,[7] chemical
sensors,[8] drug delivery,[9] and catalysis.[10]
From a structural point of view, ZIFs are
constructed by coordination between M2+
cations and imidazole (Im) anions, in which
Im acts as a linker to create connecting
bridges among the metal centers of M(Im)4
tetrahedral units.[5,11] ZIFs are mainly
prepared by solvothermal methods in both
organic[5,12] and aqueous solutions.[13]
Linker modifications or encapsulation of guest species
(e.g., nanoparticles (NPs)) within ZIFs have been com-
monly employed to control the functionality of ZIFs.
In addition, the pore size of ZIFs is simply tunable
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that, in turn, results in adjustable molecular diffusion/mass
transfer and loading of large cargoes.[14,15] This unique property
has greatly expanded the application of ZIFs in catalysis science
and drug delivery.[16,17] The crystal size and morphology of
ZIFs can also be controlled by the type of solvent and metal
salt during the synthesis process, the ratio of metal salt to
Im linker, the mixing order of the ZIF precursors, and the
addition of surfactants.[16] The stability of ZIFs under physio-
logical conditions and their pH-dependent degradability under
acidic conditions make this type of MOFs highly attractive
for the construction of pH-responsive drug delivery systems
(DDSs).[17,18] As a result of the mild acidic condition of the
tumor microenvironment (TME), ZIFs, especially ZIF-8, have
been extensively investigated as nanocarrier both in vitro and in
vivo for cancer ablation.[9,19–21] Furthermore, plenty of research
efforts have been devoted to designing novel multifunctional
ZIF-based composites both in cancer therapy[22–25] and also
in antimicrobial applications,[26–28] bioimaging,[29–31] and ther-
anostics (Scheme 1).[24] In the case of ZIF-8, as one of the
main subgroups of ZIF nanomaterials, its versatile applica-
tions is mainly due to the facile polymerization of Zn2+ and
2-methylimidazole (2-MeIm) around various objects, including
drugs,[19,32,33] NPs,[34–38] and bio-macromolecules[39,40] to render
them multifunctionality while preserving structural crystallinity
and porosity of ZIF shell.[39,41]
It deserves to be pointed out that there are many excellent
reviews summarizing the state of the art of the development
of MOFs and their applications for therapeutic, imaging, and
sensing purposes.[4,17,42–47] However, there is no comprehensive
literature review with a focus on the biomedical applications
of ZIFs.[11,21,48] In this review, we discuss the synthesis and
functionalization of ZIFs and then highlight the most recent
progresses on DDSs developed by this type of porous nanos-
tructures for chemotherapy (CT), photothermal therapy (PTT),
photodynamic therapy (PDT), antimicrobial applications, devel-
opment of theranostic nanomedicines, and biomimetic miner-
alization (Scheme 1). In addition, recent remarkable advances
on ZIF-derived nanocomposites with particular emphasis on the
multifunctional property of the nanocomposites in the treatment
and diagnosis of hard-to-treat diseases are discussed, along with
addressing critical challenges and perspectives of these materi-
als. We expect that this review can boost the knowledge of the re-
search community on the potential of ZIFs in biomedicine and
its further exploration to introduce novel nanomedicines.
2. An Overview on the Synthesis, Properties, and
Functionalization of ZIFs
ZIFs, which are very similar to aluminosilicate zeolites, are built
up tetrahedral transition metals ions, i.e., Co2+, Zn2+, Cu2+, or
Fe2+, and Im linkers where Im units make the bridges for con-
necting the metal centers.[5,11,48–51] For example, ZIF-8[5,48] and
ZIF-67[52] have been constructed by the coordination between
2-MeIm and cationic ions of Zn2+ and Co2+, respectively. ZIF-
4,[5] ZIF-7,[5] and ZIF-90[53] have also been prepared by Zn2+-Im,
Zn2+-benzimidazole, and Zn2+-imidazole-2-carboxaldehyde,
respectively.
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Scheme 1. An overview of the ZIF-based DDSs for biomedical applications. ZIF NPs can be used for the loading of the various molecules or the
fabrication of nanocomposites. For example, polymers or mesoporous silica NPs (MSNs) can be used for the preparation of core-shell nanosystems.
These porous nanostructures have been prepared by hy-
drothermal or solvothermal methods in organic solvents, such
as dimethylformamide (DMF)[5] and methanol,[12] or even in
aqueous solutions[13] with reaction temperatures ranging from
room temperature up to 200 °C, and reaction times from hours
to days.[50] Although hydrothermal/solvothermal methods are
commonly used to prepare ZIF-based nanostructures, which
are simple and easy, scaling-up of such methods is hard and
yield of the products is low.[49] To overcome the shortcomings,
sonochemical[54] and mechanochemical[55] methods have been
used to increase the yield of ZIF production. Nevertheless, due
to a high variety of controllable parameters, including synthesis
routes, concentration, and molar ratio of reactants, reaction tem-
perature, solvents, and reaction time, there is a long way to indus-
trialize the production of ZIF-8 and other members of the large
family of ZIFs. In addition, the synthesis factors for the scale-
up production of ZIFs are so far only partially investigated.[49]
Green and sustainable production of ZIFs under mild synthe-
sis conditions and the use of nontoxic solvents[13] and solvent
free methods[56,57] are very crucial from environmental protec-
tion point of view. For example, in 2017, a fast and scalable
method for the synthesis of hierarchical ZIFs, i.e., ZIF-8 and
ZIF-67, and one-pot encapsulation of dyes or proteins cargoes
using an organic base trimethylamine (TEA) was reported by
Zou and co-workers[58] The addition of TEA into the solution of
Zn(NO3)2·6H2O promoted the formation of ZnO NPs, which
rapidly transformed to ZIF-8 NPs after the addition of the 2-
MeIm as the linker.
It should be noted that among the family of ZIFs, ZIF-8 is
one of the main members that has been intensively used in
many applications, such as adsorption, catalysis, electrochemi-
cal energy storage, gas separation, drug delivery, sensing, and
electronics.[11,21] It has a sodalite-type framework with Zn2+
linked by 2-MeIm containing cages of 11.6 Å in diameter, which
are accessible through a narrow six-ring pore (3.4 Å), creating
an intrinsic porosity, which subsequently renders very large sur-
face area of 1630−1700 m2 g−1 to the ZIF-8.[5] As a result of the
ultrahigh thermal stability (stable up to 550 °C under an inert at-
mosphere), ZIF-8 is capable of maintaining its original structure
in boiling water/organic solvents for 7 days, and even it is stable
in 8 m of NaOH (aq) at 100 °C for 24 h.[5]
The functionality of ZIF-based nanomaterials can be con-
trolled by different strategies, including the modification of
linker or encapsulation of guest species, such as diverse drugs,
imagining agents, metal and metal oxide NPs or biomolecules
within ZIFs.[11,59] As an example, Lu et al.[38] reported a controlled
encapsulation strategy to incorporate various surfactant-capped
NPs with different sizes, shapes, and compositions into the ZIF-
8 NPs. Interestingly, by adjusting the time of NP addition dur-
ing the ZIF formation, the spatial distribution of the NPs within
ZIF-8 crystals was tunable. Figure 1 shows how adjusting the ad-
dition time and sequence (at the beginning (T0) or after a certain
time (T) during the growth process of ZIF-8) can affect the spatial
distribution of polyvinylpyrrolidone (PVP)-modified Au nanopar-
ticles (AuNPs) inside the ZIF-8 crystals. A similar concept has
been applied for the fabrications of various core/shell nanocom-
posites as nanotheranostic systems to simultaneously diagnose
and treat hard-to-treat diseases that have been discussed in the
next sections.[60,61]
It is also possible to coat the surface of ZIFs with stimuli-
responsive gatekeepers to precisely control the release of encap-
sulated drugs in response to pH, light or reducing agents to im-
prove therapeutic efficiency of ZIFs.[21] Ren et al. developed a pH-
and redox-responsive DDS with doxorubicin (DOX)-loaded ZIF-
8 as core and disulfide-doped organosilica as the shell.[62] The
degradation of organosilica shell was confirmed via the break-
ing down of S–S bond in the presence of tripeptide glutathione
(GSH) as a reducing agent, which is at elevated concentrations
in the cytoplasm of tumor cells. In vivo studies showed that this
DDS exhibited negligible hemolytic toxicity and significantly en-
hanced therapeutic efficiency against tumor growth compared
to the free DOX. This work also stands as a pioneering strategy
that opens new opportunities in design and fabrication of multi-
functional and stimuli-responsive DDSs based on ZIFs in cancer
treatment and diagnosis.
Although flexibility, structural diversity, mechanical and ther-
mal stability, as well as control over shape and size of the ZIFs
have held great promise in many applications, microporous
pores of ZIFs unfavorably restrict fast molecular diffusion and
mass transfer, thus limiting their utilities in catalysis, drug
delivery, and other applications.[11] Therefore, the fabrication
of mesopores or hierarchical porosity (a mixture of micro and
mesopores) in ZIFs would markedly expand their applications
as hosts to accommodate larger bulky molecules via quick
diffusion inside the porous structures.[63–69] For example, hierar-
chical ZIF-8 NPs based on surfactant–amino acid co-templating
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Figure 1. A) Schematic representation of controlled encapsulation of PVP-functionalized NPs with various sizes, shapes, and compositions into ZIF-8
crystals. The spatial distribution of the NPs within ZIF-8 crystals can be controlled by their addition sequence (i.e., addition at the beginning (T0) or after
a certain time (T) during the ZIF-8 synthesis). Spatial distributions of i) a single NP in the central areas ii) or off the central areas of the ZIF crystals,
iii) two types of NPs in the central areas, or iv) one type in the central area but the other type in the transition layers of the ZIF crystals. B) The TEM
image of the intermediate product of AuNP/ZIF-8 crystals collected after 3 h of reaction (case (i) in (A)). C) Hybrid crystals obtained when AuNPs were
introduced 15 min after the initiation of the reaction (case (ii) in (A)). D) The hybrid crystal that consists of homogeneously distributed 13 nm Au and
34 nm AuNPs in the central area, prepared by simultaneously adding of two types of the NPs at the beginning of the reaction (case (iii) in (A)). E) Hybrid
crystals that contain 34 nm AuNP-rich cores, 13 nm AuNP-rich transition layers and NP-free shells obtained by sequentially adding 34 nm AuNPs at the
beginning of the reaction and 13 nm AuNPs after 40 min (case (iv) in (A)). Reproduced with permission.[38] Copyright 2012, Springer Nature.
strategy were prepared in aqueous solution by Wu et al.[68]
They showed that cetyltrimethylammonium bromide (CTAB),
as structure-directing agent to form micelles, was not inducing
the generation of mesoporous structure, because the hydrated
zinc ions were unable to produce strong interactions with the
micelles. In contrast, in the presence of histidine aminoacid, the
interaction between the ZIF-8 precursors and CTABmicelles was
mediated by the amino acid, thus promoting the formation of
ZIF-8 network, which had mesopores interconnected by microp-
ores. Encapsulation of NPs within ZIFs and subsequent etching
is another strategy to create hierarchical macro-microporous
structures.[67,69] Based on this, polystyrene spheres (PSs) as sac-
rificial NPs, which can dissolve in the methanolic solution, were
utilized to synthesize macro-microporous ZIF-8 with cheese-like
morphology. The concentration and addition time of the en-
capsulated PSs were detrimental in controlling the ratio of the
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macropores. The introduction of the NPs into the ZIF matrix did
not change the well-defined crystal structure of the synthesized
ZIF-8.[69]
For many biomedical applications, the crystal size and mor-
phology of ZIFs are detrimental factors.[4,11,70] The type of
solvent,[53,71] metal salts,[72–74] the ratio ofmetal salt to 2-MeIm,[75]
themixing order of the ZIF precursors,[74] and the addition of sur-
factants or capping agents[76] have been reported as important
factors to control the crystal size of ZIFs.[16] It has been shown
that the reactivity of the zinc salt in the growth solution has had
a significant impact on the size of the ZIF-8 crystals.[73,74] Small
size ZIF-8 crystals (≈50–200 nm) have been harvested by using
reactive zinc salt precursors, including zinc(II) acetylacetonate
[Zn(acac)2], zinc nitrate (Zn(NO3)2), zinc sulfate (ZnSO4) or zinc
perchlorate (Zn(ClO4)2), while nonreactive salts, such as zinc
chloride (ZnCl2), zinc acetate (Zn(OAc)2) or zinc iodide (ZnI2)
produced ZIF-8 crystals with larger sizes ranging from ≈350 to
650 nm.[72] This was mainly due to the nucleation rate of ZIF
crystals, which was controlled by the coordination speed between
the metal ions and the 2-MeIm linker.[74] In fact, the solvation of
reactive salts (e.g., Zn(NO3)2) in methanolic solution is relatively
weak. Therefore, the Zn2+ ions can be rapidly coordinated by 2-
MeIm, leading to fast nucleation and subsequent generation of
small-sized NPs. Pan et al.[76] used the surfactant of CTAB as a
capping agent to control the size of ZIF-8 nanocrystals. The par-
ticle sizes were precisely tuned from ≈100 nm to 4 µm by tun-
ing of the CTAB concentration. This was attributed to the CTAB
molecules that were adsorbed on the surface of ZIF-8 crystals in
the growth solution and acted as capping agents to prevent fur-
ther crystal growth.
In order to control the morphology of ZIF NPs, two strate-
gies, i.e., nontemplated and template-mediated methods, have
been developed.[11] In the nontemplated methods, different pa-
rameters, such as solvent, metal ion to 2-MeIm ratio, and reac-
tion time have been determinant parameters in the morphol-
ogy of ZIF NPs.[77–81] For example, ordered hierarchical ZIFs
with nest-like morphology were prepared using a mixed solvent
of methanol (CH3OH) and aqueous ammonia (NH3·H2O).
[77]
The architectures with diameters of ≈2–3 µm were formed by
self-assembly of numerous nanoplates with a thickness of ≈20–
40 nm. Such structures were not produced in the presence of a
single solvent. This study demonstrated that the type of solvent
had a vital effect on the morphology of ZIFs. In contrast to the
template-free approach, the template-mediated methods employ
soft (e.g., CTAB[76]) or hard templates (e.g., PSs[82]) to control the
crystal morphology of ZIF particles. CTAB, as a capping agent,
was not only used to control the crystal size of ZIF-8,[76] but also
showed that the increase in its concentration changed the crys-
tal morphology from rhombic dodecahedron to truncated rhom-
bic dodecahedron and then to truncated cubes. In fact, the CTAB
molecules were adsorbed much more strongly on {100} faces of
ZIF-8 than the other two faces, i.e., {110} and {111}, leading to the
decrease of growth rate on the {100} face, thereby resulting in the
transformation of crystal morphology.[76] Similarly, Hu et al.[83]
obtained ZIF-67 nanocubes instead of the commonly observed
polyhedrons in the presence of CTAB as a morphological modi-
fying agent. Again, the formation of the new morphology was at-
tributed to the preferential adsorption of CTAB on the hydropho-
bic surfaces.
Given that hollow metal–organic frameworks (HMOF) have
hierarchical porous structures, accessible metal sites, and rapid
mass transport property, these types of nano/microstructures
have received great attention in many research fields, including
catalysis, gas sensors, etc.[84] Generally, three main synthetic
strategies have been developed for the construction of HMOFs,
including the exterior-templating approach (sacrificial template
fabrication technique), the self-templating method, and the two-
phase interface method. There is a comprehensive review article
describing the synthesis of HMOFs and their derivatives using
the above-mentioned approaches.[84] Inspired by HMOFs, hol-
low ZIFs (HZIFs) have also been constructed utilizing the same
strategies. For example, different types of HZIFs have been pro-
duced by the sacrificial template fabrication technique, in which
the ZIF growth on the surface of a core template was followed
by a removing step to eliminate the internal template.[82,85–87]
In addition, it is imperative to functionalize the surface of the
template prior to the ZIF growth process to enhance interaction
between the ZIF precursor and the template surface and also to
inhibit the competitive homogeneous self-nucleation of ZIFs in
the solution. For example, carboxylate-terminated PSs have been
utilized as a template for the construction of core–shell PS@ZIF-
8 composites, followed by removing the PS cores using DMF as
an etchant to obtain HZIF-8 microspheres.[85] This promising
strategy will create great opportunities for fabricating novel HZ-
IFs with diverse morphologies and unique properties in the near
future.
In the self-templating method, which is carried out in the ab-
sence of any exterior template, the generated intermediate prod-
ucts during ZIF synthesis can act as a template and direct the
formation of HZIFs.[84] In order to have better control over the
formation process of HZIFs via the self-templating method, it
is necessary to perform a surface protective modification on the
intermediate products prior to the subsequent transformation
reaction.[84] For example, Hu et al.[88] prepared HZIFs using
phenolic acids (PAs), i.e., gallic acid and tannic acid (TA). They
demonstrated that PAs not only acted as the surface protecting
agents, but also served as an etching agent to create HZIF-8 with-
out destroying the crystallinity of the parent ZIF. In fact, the
outer shell of the ZIF-8 was protected by the PAs that blocked
the exposed surface of ZIF-8 and the inner part was etched by
free H+ ions released by the PAs.[89] The HZIFs produced heat
upon irradiating to the near-infrared (NIR) light (808 nm), poten-
tially endowing them with photothermal therapy capability.[89] In
the two-phase interface method, which is more convenient, the
interface of two different phases is employed as a template for
growing of ZIF at the interface. This method is classified into
three categories: liquid–liquid, solid—liquid, and gas–liquid in-
terface systems, which all have been reported for the synthesis of
HZIFs.[66,90,91]
Although, there are successful achievements on controlling
the pore size, diameter, morphology and surface properties of
ZIFs, the reaction parameters have not been systematically op-
timized and there is no clear guideline for controlling the par-
ticle diameter, pore size, and morphology. In addition, most of
the current studies have focused only on the ZIF-8. Therefore,
further studies are needed on the physicochemical properties
of other ZIFs rather than ZIF-8, because the developed tech-
niques are still at an infancy stage. In this context, reproducibil-
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ity, cost-effective preparation and environmental considerations
of the synthesis methods must receive more attention in future
studies.
3. ZIF NPs for pH-Responsive Therapy
The design and construction of novel DDSs have been grown
in recent years with central attention devoted to new methods
for developing stimuli-responsive DDSs.[92,93] Among different
types of stimuli, such as temperature, electric field, light, and
magnetic field,[94] pH-sensitive DDSs have been the main core
of numerous investigations to develop responsive nanosystems,
specifically for cancer therapy goals.[92] This is mainly due to
the pH of tumor tissue (pH 5.5–6.0), which is more acidic than
the blood and normal tissues (pH 7.4). Such nanosystems have
been employed to transport toxic chemotherapeutic drugs to can-
cer site via blood circulation with minimum undesired drug re-
lease before reaching the cancer tissue.[92,95] However, many of
the systems suffer from low drug-loading capacity, poor biocom-
patibility, undesirable biodegradability, and complicated synthe-
sis procedures. As a result of the unique properties of MOFs,
this type of porous materials has attracted great attention for
achieving a controllable drug release.[4,17] Generally, the encap-
sulation of drug of interest into MOFs involves several steps, in-
cluding synthesis ofMOF carriers, removal of solvents from their
pores, and finally loading of the cargos, which all together make
the whole process costly and complicated.[96] Furthermore, the
small pore apertures of MOFs limits the entering of large car-
goes within the network of MOF.[42,44,97] Recently, ZIFs have suc-
cessfully been used as drug carriers in the construction of varied
DDSs that can load a range of cargos from small molecule drugs
to large bio-macromolecules, such as enzymes and proteins for
pH-responsive drug delivery (Table 1).[9,18,21,98]
In this section, we provide the most significant signs of
progress in the development of simple ZIF-basedDDSs in cancer
therapy, antibacterial applications, and biomineralization. ZIFs
loaded by a cargo, and/or in some cases functionalized by small
molecules and polymers, e.g., polyethylene glycol (PEG), are
discussed. The components, structures, and properties of ZIFs
are highlighted in different examples. In addition, the impact of
the ZIF framework, especially the degradation of the network in
acidic environments, is discussed along with benefits and critical
challenges of each system. In contrast, Section 4 has a focus on
the complex multifunctional DDSs derived from ZIF-based com-
posites, integrated/functionalized by somemetal NPs, nanorods,
mesoporous silicas, quantum dots, polymers, or graphene to
form core@shell or hybrid structures for various biomedical
applications.
3.1. Applications of ZIF NPs in Cancer Therapy
For the first time, Sun et al.[9] demonstrated that ZIF-8 could be
used for the delivery of anticancer drugs in vitro. Remarkable
loading of 660 mg of 5-FU in 1 g of ZIF-8, and pH-triggered
controlled release of the drug, which was much faster in acidic
condition (pH 5) than neutral one (pH 7.4), were observed,
suggesting ZIF-8 as an excellent pH-sensitive DDS.[9] However,
as the pore window of ZIF-8 is 3.4 Å, this structural feature limits
the entrance of large molecules inside the pores, thus leading
to low cargo loading within the pores and burst release, as a
result of drug adsorption on the surface of the particles.[37,119]
In order to tackle this hurdle, a simple process that combined
ZIF synthesis and cargo encapsulation in a one-pot manner was
reported by Zheng et al.[100] In this process, the anticancer drug
DOX and three organic dyes, were successfully encapsulated
within ZIF-8 and ZIF-67 with high cargo loading (14–20 wt%).
Firstly, the metal ion and dye/drug molecules self-assembled to
form coordination polymers. After the addition of the organic
linkers, the coordination polymers disassembled, and thus, the
subsequent generation of ZIF network caused to encapsulating
of target molecules within the ZIF hosts. The drug/dye-loaded
crystals possessed hierarchical pore structures containing or-
dered micropores and homogeneously distributed mesopores
filled by the guests. Interestingly, hierarchical micro and meso-
porous ZIF-based structures were harvested by the removal
of the organic drug/dyes from the pores. DOX-loaded-ZIF-8
showed pH-responsive release behavior, in which the drug was
not released under physiological condition (pH 7.4), while the
release of the drug occurred in a controlled manner at lower
pH values of 5.0−6.5. Cytotoxicity assays on breast cancer cell
lines showed that the DOX@ZIF-8 had higher toxicity than
that of free DOX.[100] In a different study on the controlled
release behavior of DOX-loaded into ZIF-8 and ZIF-7, it was
shown that ZIF-8 released the drug in a more controlled man-
ner than ZIF-7 under acidic condition, demonstrating that
ZIF-7 was more stable at acidic pH than the ZIF-8 carrier,
highlighting the effect of ZIF type in the design of controlled
DDSs.[20]
Despite excellent advantages of ZIFs, low dispersity, cytotox-
icity, and aggregation of the MOFs under physiological condi-
tion, nonactive targeting capability, and concerns related to its
favorable biocompatibility have seriously limited their in vivo
applications.[102,120,121] In order to overcome these limitations,
several studies have been demonstrated the surface function-
alization of the ZIFs by folic acid (FA)-PEG,[108,110] hyaluronic
acid (HA),[105] phenolic lipid,[120] peptide,[122] and phospho-
lipid bilayer.[102] HA, a targeting ligand of the CD44 recep-
tor, is overexpressed in many growing tumor cells. This ligand
was attached on the surface of curcumin (CCM)-loaded ZIF-
8 through coordinative interaction to promote the cellular up-
take of NPs. The surface modification endowed the nanocom-
posite (CCM@ZIF-8/HA) with active targeting ability and en-
hanced its biocompatibility. The CCM@ZIF-8/HA showed en-
hanced dispersity in phosphate buffer saline (PBS) and a long-
term pH-responsive drug release behavior and successfully de-
livered CCM into cancer cells.[105] Efficient autophagy inhibi-
tion was observed by chloroquine (CQ), as autophagy inhibitor,
-loaded ZIF-8 (CQ@ZIF-8) after functionalization by methoxy
FA-PEG. Compared to healthy cells (HEK293 cells), the cancer
cells (HeLa cells) showed lower viabilities when treated with FA-
PEG/CQ@ZIF-8 NPs, demonstrating targeting ability of FA and
inhibiting the process of autophagy flux in the cancer cells, as
well as the formation of autophagosome more effectively than
the free CQ and CQ@ZIF-8.[108]
Adv. Healthcare Mater. 2020, 9, 2000248 2000248 (6 of 42) © 2020 The Authors. Published by WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim
www.advancedsciencenews.com www.advhealthmat.de
Table 1. Summary of ZIF-based pH-responsive DDSs.
Type of ZIF and
surface ligand
Encapsulated
Cargo
Size [nm/µm]; Zeta
potential [mV]
Cells and animal models Main conclusion Ref.
ZIF-8 5-FU Before loading:
<200 µm
ND – The first example of the application of ZIFs in DDSs.
– Remarkable capacity for the 5-FU loading.
– pH-triggered 5-FU release for cancer chemotherapy.
[9]
ZIF-8 CPT and FES Before FES loading:
70 nm; +31.4 mV
After FES loading:
70 nm; +31.0 mV
In vitro: Epithelial MCF-7
breast cancer cells
– Moderate cytotoxicity of the ZIF-8 NPs which was
comparable to other organic and inorganic drug
carriers.
– pH-triggered disintegration of the ZIF-8 NPs in
acidic condition.
– The versatility of the fabrication method for the
encapsulation of the organic dyes, anticancer drugs,
and magnetic NPs within the ZIF-8 NPs.
– Increased cell death by CPT-loaded ZIF-8 as
compared to the free CPT.
[18]
ZIF-8 Caffeine Before loading:
200–300 nm; ND
After loading:
200–300 nm; ND
ND – One-step, in situ encapsulation of caffeine within
ZIF-8 NPs
– High caffeine loading (≈28 wt% in only 2 h at
25 °C).
[99]
ZIF-8 CCM Before loading:
ND; +4.4 mV
After loading:
119.3 ± 13.6 nm; +4.3 mV
In vitro: HeLa cell line
In vivo: U14 cervical cancer
model
– CCM-loaded ZIF-8 NPs possessed good chemical
stability, high drug encapsulation efficiency (88.2%),
and fast drug release in tumor acidic media.
– Higher cytotoxicity of CCM-loaded ZIF-8 NPs than
free CCM both in vitro and in vivo.
[19]
ZIF-8 and ZIF-67 DOX and dye
molecules
Before loading:
ND
After DOX loading within
ZIF-8:
nm 70–300 nm;
+30.1–+31.1 mV
In vitro: Epithelial MCF-7
breast cancer cells,
epithelial MDA-MB-231,
and MDA-MB-468
– A novel approach combining ZIF synthesis and
cargo (large drugs and dye molecules)
encapsulation in a one-pot step.
– Efficient cancer therapy using DOX-loaded ZIF-8
through a pH-responsive drug release.
[100]
ZIF-7 and ZIF-8 DOX ND ND – Successful encapsulation of DOX within ZIF-7 and
ZIF-8.
– When pH increased from physiological condition to
acidic condition, ZIF-7 remained intact whereas
ZIF-8 released DOX in acidic condition.
[20]
ZIF-8 5-FU Before loading:
≈200 nm; +21.0 mV
In vitro: Epithelial HepG2
cells, epithelial 4T1 cells,
and epithelial MCF-7
breast cancer cells
In vivo: 4T1 mammary
gland breast cancer
model
– Concentration and time-dependent cellular uptake
of ZIF-8 NPs was affected by the particle size of the
NPs, but not by drug loading.
– Clathrin and macropinocytosis-mediated pathways
were involved in the cellular uptake of the
ZIF-8-NPs.
– The unexpected high concentration of ZIF-8 NPs
was found in lung, probably due to the particle size.
– At the normal doses, ZIF-NPs exhibited acceptable
biocompatibilities, and minimal effects on the renal
and liver functions, inflammatory factors, and
immune cells.
– 5-Fu-loaded ZIF-8 NPs significantly improved the
therapeutic outcome in a mouse model with tumor
lung metastasis.
[70]
ZIF-8 CCM Before loading:
140 ± 5 nm; +7.40 mV
After loading:
145 ± 5 nm; +7.22 mV
In vitro: HeLa cell line – ZIF-8 NPs exhibited ultrahigh CCM encapsulation
efficiency (≈83.33%) and good chemical stability.
– Cellular internalization of CCM-ZIF-8 in HeLa cells
was confirmed by CLSM.
[101]
ZIF-4@DOPC CCM Before loading:
120 nm; −20.5 mV
After loading:
141 nm; ND
ND – The CCM-loaded ZIF-4@DOPC showed remarkable
water dispersity and stability in PBS.
– The ZIF-4@DOPC possessed high drug entrapment
efficiency (80.8%) and the release of CCM from the
carrier was pH-responsive.
[102]
(Continued)
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Table 1. Continued.
Type of ZIF and
surface ligand
Encapsulated
Cargo
Size [nm/µm]; Zeta
potential [mV]
Cells and animal models Main conclusion Ref.
ZIF-8 6-MP Before loading:
516 nm; ND
After loading:
566 nm; ND
ND – Owing to the pH-degradability of ZIF-8 NPs in
acidic condition, much faster 6-MP release occurred
from the 6-MP@ZIF-8 in acidic pH as compared to
the release medium with the pH value of 7.4.
[103]
PEG-FA-modified
ZIF-8
DOX and VER After loading:
185 nm; −34.5 ± 7.43 mV
In vitro: B16F10 melanoma
cells and epithelial
MCF-7 breast cancer
cells
In vivo: B16F10 melanoma
model
– Successful co-delivery to overcome multidrug
resistance (MDR) cancer.
– Prolonged blood circulation and active targeting.
– Desirable NIRF imaging
[33]
ZIF-8 CpG ODNs Before loading:
342 nm; ≈+20 mV
After loading:
396 nm; ≈+5 mV
In vitro: RAW264.7
macrophage cells
In vivo: quantification of
inflammatory cytokines
in blood samples
– CpG ODNs-ZIF-8 complexes showed good stability
in physiological condition and effective release of
CpG ODNs in an acidic environment.
– Intracellular uptake of CpG ODNs was significantly
increased by ZIF-8 NPs in RAW264.7 cells, thus
enhancing the secretion of immune cytokines both
in vitro and in vivo, confirming potent
immunostimulatory activity of the nanosystem.
[104]
HA/IM-modified
ZIF-8
CCM After loading:
159.2 nm; −28.1 mV
In vitro: HeLa cell line – CCM-loaded HA/IM-modified ZIF-8 NPs exhibited
enhanced dispersity in PBS, promoted cellular
uptake, and higher growth inhibition against HeLa
cells than the bare CCM@ZIF-8 NPs.
[105]
ZIF-8 MLT Before loading:
≈100 nm; +13.8 mV
After loading:
≈100 nm; +14.4 mV
In vitro: Epithelial A549
Cells and HeLa cell line
In vivo: U14 cervical cancer
model
– Loading into ZIF-8 NPs could reduce the
undesirable hemolytic activity of the MLT.
– Mechanistic investigations through transcriptome
analysis showed that MLT@ZIF-8 NPs could
regulate the expression of 3383 genes, and the
PI3K/Akt-regulated p53 pathway, which involved in
the apoptosis of A549 cells.
– The MLT@ZIF-8 NPs showed enhanced anticancer
activity than the free MLT in vivo.
[106]
AS1411 aptamer-
modified
ZIF-8
DOX After loading:
100 nm; −10 mV
In vitro: HeLa and epithelial
HEK 293T cells lines
– The DOX-loaded AS1411 aptamer-modified ZIF-8
DDSs could effectively escape from the
endo/lysosomal vesicles due to the pH-triggered
release of zinc ions and the ROS production,
synergistically enhancing the cancer therapy.
[32]
RGD-modified
ZIF-8
CPT After loading:
100 nm; ≈+12 mV
In vitro: HeLa cell line – The CPT-loaded RGD-modified ZIF-8 NPs exhibited
favorable biocompatibility and excellent
pH-responsive CPT release.
– Intracellular ROS generation of the DDS enhanced
cancer cell death in vitro.
[107]
PEG-FA-modified
ZIF-8
CQ After loading:
250 nm; −6.05 mV
In vitro: HeLa and epithelial
HEK 293 cells lines
– Due to the targeting property of FA, the CQ-loaded
PEG-FA-modified ZIF-8 (FA-PEG/CQ@ZIF-8) NPs
reduced the viabilities of HeLa cells compared to
the nontargeted counterparts.
– The pH-responsive PEG-FA/CQ@ZIF-8 NPs could
control the CQ release and enhanced the efficiency
of the autophagy inhibition.
[108]
ZIF-8 3-MA Before loading:
90 nm; 24.1 ± 5.5 mV
After loading:
80 nm; 3.2 ± 2.2 mV
In vitro: HeLa cell line
In vivo: cervical cancer
HeLa model
– An effective autophagy inhibition and tumor
targeting was mediated by encapsulating 3-MA, an
autophagy inhibitor, into the ZIF-8 (3-MA@ZIF-8).
– Compared to free 3-MA, the 3-MA@ZIF-8 NPs
severely blocked autophagosome formation and
autophagy flux.
– More control over precise drug release and more
efficient antitumor effect and autophagy inhibition
was observed in the xenograft tumor model for the
3-MA-loaded ZIF-8 NPs.
[109]
(Continued)
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Table 1. Continued.
Type of ZIF and
surface ligand
Encapsulated
Cargo
Size [nm/µm]; Zeta
potential [mV]
Cells and animal models Main conclusion Ref.
PEG-FA-modified
ZIF-8
PEGCG After loading:
220 nm; −21.9 ± 0.36 mV
In vitro: Hela and epithelial
HEK 293 cells
– Compared to free PEGCG, PEGCG-loaded
PEG-FA-modified ZIF-8 NPs showed higher
anticancer effect via excellent induction of
autophagic death on tumor cells.
[110]
ZIF-8 Ceftazidime ND In vitro: Bacteria killing
effect on E. coli
– Antibacterial properties of ceftazidime@ZIF-8 NPs
were observed against E. coli.
– Taking the advantage of the intrinsic emission
properties of ZIF-8 NPs, for the first time, this study
showed the internalization of the NPs using CLSM
via 3D reconstructions of z-stacks.
[111]
ZIF-8 RFP and
o-NBA
Before loading:
≈100 nm; +30.5 mV
After loading:
≈200 nm; +27.0 mV
In vitro: killing effect of the
NP on
ampicillin-resistant E.
coli and MRSA
In vivo: Infected wound
– pH and light-triggered drug delivery.
– High antibacterial effect through combination
therapy.
– Accelerated wound healing in vivo.
[26]
ZIF-8 Physcion Before loading:
157 nm; +6.5 mV
After loading:
165 nm; +6.5 mV
In vitro: Bactericidal effects
on P. Putida, E. coli,
engineered E. coli
(QH4), and S. Aureus
– Compare to free PHY, PHY-loaded@ZIF-8 NPs
showed maximum growth inhibition zones against
both Gram-negative and Gram-positive strains.
[112]
ZIF-67 and
Co-SIM-1
ND Before loading for both
ZIF-67 and Co-SIM-1:
≈2 µm; ND
In vitro: Bactericidal effects
of the drug-loaded NPs
on S. cerevisiae, P. putida,
and E. coli
– The control release of metal endowed the DDSs
with excellent antibacterial activities against gram
negative bacteria.
[113]
FA-modified
ZIF-8
Vancomycin Before loading:
50 nm; ND
After loading:
75 ± 10 nm; ND
In vitro: killing effect of the
drug-loaded NPs on
MDR S. aureus and E. coli
– The presence of FA on the surface of the
vancomycin-loaded ZIF-8 NPs could significantly
increase the effective uptake of the NPs into MDR S.
aureus through endocytosis, thus enhancing
antibacterial activity.
[114]
ZIF-8 Iodine Before loading:
550 ± 103 nm; ND
After loading:
530 ± 105 nm; ND
In vitro: Bactericidal effects
of the drug-loaded NPs
on S. epidermidis, S.
aureus, and E. coli
– Due to the acid degradability of the ZIFs, both the
Gram-negative and Gram-positive bacteria could be
very effectively killed by the iodine-loaded ZIF-8 at
pH 6.0, while at pH < 7.0, no appreciable
antibacterial activity was observed.
[115]
ZIF-8 SQ Before loading:
180 nm; ND
After loading:
170 nm; ND
In vitro: Killing effect of
SQ-loaded ZIF-8
(SQ-ZIF-8) NPs on
MRSA
– SQ-ZIF-8 NPs produced cytotoxic ROS under red
light irradiation (650 nm) through a pH-sensitive
manner to kill MRSA bacteria, leading to complete
loss of adherence of structurally robust bacterial
biofilms.
[116]
ZIF-8 Indocyanine
green
Before loading:
≈40 nm; ND
After loading:
≈100 nm; ND
In vitro: Bactericidal effects
of the drug-loaded NPs
on MRSA
In vivo: Infected skin
– Zinc ions released from ZIF network could inhibit
bacterial growth by increasing the permeability of
bacterial cell membrane.
– Remarkable bactericidal activity was observed by the
chemo-photothermal therapy in vivo.
[117]
Cu2+-modified
ZIF-8
CCM Before loading:
≈100 nm; ND
After loading:
≈200 nm; ND
In vitro: Killing effect of the
drug-loaded NPs on
E. coli
– ROS generation was boosted due to combined
interactions of Zn2+ and Cu2+.
– CCM-loaded ZIF-8 NPs exhibited greater
anti-biofilm and anti-bacterial effects than free CCM.
[118]
Abbreviations: 3-MA: 3-methyladenine; 5-FU: 5-fluorouracil; 6-MP: 6-mercaptopurine; CCM: curcumin; CDT: chemodynamic therapy; Co-SIM-1: cobalt-based substituted
imidazolate material; CpG ODNs: CpG oligodeoxynucleotides; CPT: camptothecin; CQ: chloroquine diphosphate; DOPC: 1,2-dioleoyl-sn-glycero-3-phosphocholine; E. coli:
Escherichia coli; FA: folic acid; FA-PEG: methoxy poly(ethylene glycol)-folate; FES: fluorescein; HA: hyaluronic acid; HA/IM: imidazole substituted hyaluronic acid; HeLa cell
line: human epithelial carcinoma cells; MDR: multidrug resistance; MLT: melittin; MRSA: methicillin-resistant Staphylococcus aureus; ND: not determined; NIRF: near in-
frared fluorescent imaging; o-NBA: 2-nitrobenzaldehyde; PBS: phosphate buffer saline, P. Putida: Pseudomonas putida; PEGCG: epigallocatechin-3-gallatea palmitate; PEG-FA:
methoxy poly (ethylene glycol)-folate; RGD: Arg-Gly-Asp; ROS: reactive oxygen species; S. cerevisiae: Saccharomyces cerevisiae; S. aureus: Staphylococcus aureus; S. epidermidis:
Staphylococcus epidermidis; SQ: squaraine; VER: verapamil hydrochloride.
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Surface chemical functionalization of ZIFS with safe materi-
als can increase their biocompatibility; however, it might reduce
pore sizes or even block the pores. Zhao and co-workers, used
a mechanical ball-milling method to develop a surface defection
strategy on the external surface of ZIF-8 to tune the hydrophobic–
hydrophilic balance of ZIF-8, resulting in significantly higher
cell viability without decreasing its cargo loading and release
capacity.[123] In the mechanical ball-milling method, unsaturated
Zn-sites and N-sites were created on the external surface of ZIF-
8, leading to the binding of H2O molecules on the surface and
generating a hydrophilic surface that significantly improved cell
viability of ZIF-8.
Horcajada and co-workers evaluated the cytotoxicity of a se-
ries of MOF NPs on two cell lines (J774 and HeLa) by the MTT
assay and indicated that the cytotoxicity was strongly depended
on the MOF composition since Fe-based MOFs exhibited less
toxicity than the Zn- or Zr-MOF NPs.[121] Recent toxicological
investigations suggested that toxicity of Zn was related to the
high solubility of Zn2+ cations.[124] Therefore, the research group
proposed that ZIF-8 NPs were progressively degraded into Zn2+
and 2-MeIm in cell culture media containing phosphates ions
and in the acidic endosomal environment. The high toxicity of
ZIF-8 was related to the competition of the released/dissolved
Zn2+ with Fe2+ and Ca2+ ions through ion channels and/or DNA
damage.[121] These observations highlighted the importance of
surface modification of the ZIFs to overcome the toxicological
concerns.
A series of pharmacokinetics and biodistribution studies of
ZIF-8 NPs were conducted by Zhang and co-workers to under-
stand biofate of the NPs within the body.[70] After intravenous
administration to rats (32 mg kg−1), the serum zinc concentra-
tion steadily declined over time and elimination half-life was
3.6 h with a clearance of 0.187 L h−1 g−1. Low accumulation of
Znwas detected in tissues, including the kidney, heart, brain, and
testis (up to ≈25 µg g−1). In contrast, ZIF-8 NPs were captured
much more by reticuloendothelial system (RES) organs (up to
≈210, ≈35, and ≈32 µg g−1 in the lung, liver, and spleen, respec-
tively). Unexpected accumulation of Zn in the lung was probably
due to the particle size of the NPs. However, after 7 days, the
concentration of Zn in the RES tissues decreased dramatically,
suggesting the fast degradation and elimination of the NPs. In
addition, around 65% and 12% of the NPs were eliminated by fe-
ces and urine within 7 days, respectively. Interestingly, due to the
high pulmonary accumulation and fast elimination of the NPs,
the 5-Fu-loaded ZIF-8 NPs had a significant therapeutic effect on
a tumor lung metastasis bearing mouse model. Significant accu-
mulation of ZIF-8@DOX in the lung was also reported by Cheng
et al., which can be used for the chemotherapy of lung cancer.[125]
This phenomenon was related to the aggregation of the NPs in
the blood circulation, leading to the entrapment of the nanosys-
tem in abundant capillaries of the lung. Interestingly, after coat-
ing of the NPs with 4T1 cancer cell membrane, accumulation in
the lung was remarkably decreased, highlighting importance of
the biomimetic coating in enhanced biocompatibility of the ZIF-
based DDSs.
Although there are extensive studies on the applications of
ZIFs in cancer diagnosis and treatment, the most attention has
mainly focused on ZIF-8. In order to exploit other members of
the ZIF family, Jiang et al.[126] synthesized nanoscale ZIF-90 with
a negative zeta-potential, which exhibited better cell biocompat-
ibility, mitochondria targetability, and in vivo survival rate com-
pared to the ZIF-8 NPs with positive zeta-potential. In addition,
in vivo toxicity studies confirmed the excellent biocompatibility of
ZIF-90 and minimal side effects on the renal and liver functions.
The surface of DOX-loaded ZIF-90 NPs was surface-modified
by Y1 receptor ligand [Asn6, Pro34]-NPY (AP) to realize targeted
adenosine triphosphate (ATP) and induce in vivo pH-responsive
triple-negative breast cancer treatment. ATP-responsive property
of the nanosystem was due to the stronger coordination between
ATP and Zn2+ than the Im and Zn2+, enhancing the therapeutic
efficacy of the nanosystem in the killing of cancer cells. Naturally,
the concentration of ATP in the tumor cells is ≈100 times higher
than the normal cells, allowing the targeting of ATP for cancer
therapy.[127,128]
Multidrug resistance (MDR) is one of the important hurdles
inhibiting effective cancer chemotherapy.[129] This phenomenon
mainly originates from either an acquired resistance in can-
cer cells by the stimulus of anticancer drugs to overexpress
ATP-binding cassette (ABC) transporter (e.g., p-glycoprotein (p-
gp)) or intrinsic high expression of ABC transporter proteins.
This overexpressed transporter can efflux the chemotherapeu-
tic drugs from the cytoplasm of cancer cells to reduce their ac-
cumulation within the cells, resulting in an extremely low ther-
apeutic outcome.[130,131] To circumvent MDR, the combination
of small molecule anticancer drugs or chemosensitizers with
macromolecular therapeutic genes, in a single DDS is an effi-
cient way to treat cancer.[130] As a result of the inherent bio-
compatibility and pH-degradability of ZIF-8, this porous mate-
rial was employed to construct a co-delivery nanosystem con-
taining DOX and verapamil (VER) to overcome MDR in tu-
mor cells for achieving efficient in vivo cancer therapy.[33] The
(DOX+VER)@ZIF-8 was further functionalized by methoxy poly
FA-PEG to avoid aggregation of (DOX+VER)@ZIF-8 particles,
and thus, prolonging its blood circulation as an active DDS (Fig-
ure 2A). VER, as a p-glycoprotein inhibitor, could reverse the drug
resistance associated with p-glycoprotein, resulting in increased
local concentrations of DOX in MDR tumor cells and improving
the efficiency of the formulation. Transmission electron micro-
scope (TEM) images showed that PEG-FA/(DOX+VER)@ZIF-
8 particles had uniform spherical-like morphology and the di-
ameter of the NPs was determined to be 185 nm with narrow
size distribution (Figure 2B). For both DOX and VER, faster
drug release in acidic condition (pH ≈ 5.0) compared to the
neutral release medium (pH ≈ 7.4) was observed from the
(DOX+VER)@ZIF-8 NPs, confirming the degradation of ZIF-8
in the acidic environment and drugs release acceleration. Cyto-
toxicity assay on B16F10 and MCF-7/A cells showed that the in-
hibition rates of PEG-FA/(DOX+VER)@ZIF-8 were higher than
that of free drug of DOX and DOX@ZIF-8 NPs (Figure 2C).
This fact was attributed to the targeting property of the folate
ligand and the role of VER in overcoming the drug efflux me-
diated through the overexpressed p-gp in MDR cancer cells,
i.e., MCF-7/A cells. Fluorescence inverted microscopy showed
that PEG-FA/(DOX+VER)@ZIF-8 NPs have a higher intensity
of red fluorescence than (DOX+VER)@ZIF-8 NPs in MCF-7
cells, confirming the specific binding between folate ligand and
overexpressed FA receptors on the cancer cells. In agreement
with fluorescence inverted microscopy, flow cytometry analy-
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Figure 2. A) Schematic depiction of PEG-FA/(DOX+VER)@ZIF-8 synthesis and accumulation in tumor site via the enhanced permeability and retention
(EPR) effect are shown in the left. The uptake of the DDS by tumor cells via folate receptors, pH-degradability of the DDS under the acidic tumor
microenvironment, and MDR reversal mediated by VER are shown in the right schematic. B) The TEM image of PEG-FA/(DOX+VER)@ZIF-8 NPs. C)
The cell inhibition rates (%) of different formulations to B16F10 and MCF-7/A cells after treatment for 24 h (0.01 ≤ *p < 0.05, **p < 0.01, n = 3). D)
Time-dependent tumor growth curves after different treatments. E) Photographs of excised tumors of mice bearing melanoma and treated with different
formulations. Reproduced with permission.[33] Copyright 2017, American Chemical Society.
sis proved that the cellular uptake of (DOX+VER)@ZIF-8 NPs
into p-gp-overexpressed MCF-7 cells was higher than free DOX
and DOX@ZIF-8, demonstrating the inhibitory effect of VER
on drug efflux induced by p-gp. As shown in Figure 2D, differ-
ent formulations were studied in vivo. Among all the formu-
lations, the mice treated by PEG-FA/(DOX+VER)@ZIF-8 NPs
exhibited the best tumor inhibition effect. This behavior was
also confirmed by the tumors dissected and photographed af-
ter the last injection (Figure 2E), ascribed to the pH-responsive
property of the NPs, active targeting capability via FA and the
MDR reversal mediated by VER. Altogether, this DDS broad-
ened the applications of ZIFs in the biomedical field and was an
efficient formulation in reversing the MDR for targeted cancer
therapy goals.
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3.2. Antibacterial Applications of ZIFs
MOFs have extensively been used as bactericidal agents through
the release of antimicrobial metal ions (e.g., Ag+, Zn2+, and
Co2+) or antimicrobial agents from their framework.[43] It has
been shown that particle size, shape, zeta-potential and chemical
properties of NPs have a significant impact on their antibacte-
rial activity.[132,133] As particle size, morphology, and composition
of the MOFs are tunable, there is a great opportunity to treat
various microbial infections by adjusting their physicochemi-
cal properties, a unique benefit that is difficult to achieve by
conventional antibiotics.[27,43] Although MOFs have huge sur-
face area and high porosity, their small pore size limits the
loading of large molecules via post-synthetic methods. The ac-
cess to MOFs containing large pore apertures is challenging
yet and needs complicated synthesis procedures.[15,64,134–136] As
mentioned above, ZIFs can encapsulate many organic/inorganic
cargos via growing around the guests, while maintaining the
functionality of the cargos.[100] ZIFs have been successfully
employed to encapsulate antibiotics, such as ciprofloxacin,[137]
gentamicin,[138] physcion,[112] ceftazidime,[111] and vancomycin
(Van)[114] for antimicrobial therapy. For example, Song et al.[26]
prepared 2-nitrobenzaldehyde (o-NBA) and rifampicin (RFP)-
loaded ZIF-8 (o-NBA-RFP@ZIF-8) through a one-potmethod for
light-controlled antibacterial therapy. Under UV-light treatment
(365 nm), o-NBA was converted to 2-nitrosobenzoic acid, thus
serving as pH-jump reagent to generate an acidic environment
and degrade the ZIF-8 network, leading to burst release of RFP
antibiotic and Zn2+ and, ultimately, resulting in synergistic an-
tibacterial therapy to inhibit bacteria-induced wound infection
and promoting wound healing (Figure 3A). In the presence UV-
light, TEM images proved the pH-dependent degradation of o-
NBA-RFP@ZIF-8 NPs (Figure 3B). Light-triggered antibiotic re-
lease studies revealed no drug release from RFP@ZIF-8 NPs in
the absence of o-NBA (Figure 3C). In contrast, a maximum of
80 wt% of RFP was released within 150 min upon UV-light ir-
radiation of the o-NBA-RFP@ZIF-8 NPs, confirming pH depen-
dency of the drug release by in situ light-mediated acid genera-
tion (Figure 3C) and subsequent ZIF network dissolvation and,
thus, pH decreasing and production of Zn2+ ions in the release
medium (Figure 3D,E).
As shown in Figure 3F, in vitro antibacterial assays showed
that o-NBA-RFP@ZIF-8 had higher antibacterial activity against
both the Gram-positive methicillin-resistant Staphylococcus au-
reus (MRSA) and Gram-negative ampicillin-resistant Escherichia
coli than the other samples under UV-light treatment. This was
attributed to the synergistic effect between the antibiotic and
Zn2+ ion released from the o-NBA-RFP@ZIF-8. In vivo antibac-
terial efficacy was evaluated by MRSA and ampicillin-resistant
E. Coli-induced wound infection model on the back of BALBc
mice. As shown in Figure 3G, the wound size using o-NBA-
RFP@ZIF-8 as a treatment agent under UV-light irradiation de-
creased much faster (80%) than the other groups. In the group
treated with the o-NBA-RFP@ZIF-8 + light, well-established col-
lagen fibers and dermal layer formation was confirmed by Mas-
son’s trichrome staining, demonstrating high efficacy of the syn-
ergistic treatment to eradicate the infection, promote derm gen-
eration, and modulate the collagen alignment, thus leading to
accelerated wound healing.[26]
3.3. ZIFs for Biomimetic Mineralization
Biomimetic mineralization (bio-min) with MOFs is an emerg-
ing and robust strategy to shield sensitive biological materials
toward enhanced thermal stability, protection against denatur-
ing proteolytic agents/mechanical stress/UV radiation and ex-
tended shelf-life time.[41,139–143] Using this strategy, many en-
capsulated bio-macromolecules including enzymes,[39,41,144–152]
proteins,[40,153–159] vaccines,[160–162] antibodies,[163] or even more
complex living systems[139,164–167] (e.g., bacteria, viruses, and eu-
karyotic cells) have been made with enhanced bioactivity and sta-
bility. For the first time, a rapid and low-cost bio-min method
was introduced by Liang et al.[143] as a protective approach for the
coating of bio-macromolecules. They showed that a wide variety
of bio-macromolecules, including enzymes, proteins, and DNA
could successfully be encapsulated withinMOFs framework. The
resulting biocomposites were stable and kept their activity even
after exposure to harsh conditions. The change of pH was used
to control the release of the cargos from the MOF-coated bio-
macromolecules. For the bio-min process, ZIF NPs, especially
ZIF-8, have been shown to be a superior candidate to protect bio-
macromolecules under the mild condition of the biomineraliza-
tion process.[41] For example, the bio-min of ZIF-8 can be per-
formedwithin a fewminutes in aqueous solutions and under am-
bient temperature without using toxic organic solvents.[158] How-
ever, despite many examples available on bio-min of diverse bio-
macromolecules, the mechanism of such bio-min has not fully
been investigated.[143]
Enzymes are efficient and environmentally benign cata-
lysts that can selectively catalyze different biological pro-
cesses to produce various chemicals and pharmaceutically ac-
tive medicines.[168] However, their unfavorable stability against
heat and organic solvents and undesirable recyclability have
limited the use of enzymes toward practical applications.[41]
Therefore, the immobilization of enzymes within a porous
matrix is a straightforward and efficient method to solve
the above-mentioned problems and improve the performance
of enzymatic reactions.[41,141] ZIFs have been able to en-
capsulate various enzymes, such as lipase,[144,169] horseradish
peroxidase,[145,147] catalase,[38,148,149,170] glucose oxidase,[39,145–147]
chloroperoxidase,[146] lysozyme,[143] cytochrome c,[156] and 𝛽-
galactosidase,[147] to render them high stability. In this condition,
the porous shell allowed substrates to diffuse through the pores
and undergo catalysis by the caged enzyme, while keeping the in-
laid enzyme fromdenaturation by various chemicals. It should be
added that two or even three enzymes have been simultaneously
embedded in ZIF NPs, acting as nanoreactors in biocatalytic cas-
cades transformations.[145–147]
In 2018, Chen et al.[39] fabricated two smart glucose-responsive
DDSs based on ZIF-8 NPs. In the first system, glucose oxidase
(GOx) enzyme and insulin protein were loaded within ZIF-8
NPs in a one-pot method, while the second nanosystem was
composed of anti-vascular endothelial growth factor (VEGF) ap-
tamer and GOx co-encapsulated into the ZIF-8 NPs. In the pres-
ence of glucose, GOx-mediated aerobic oxidation of glucose to
H2O2/gluconic acid and subsequent creation of an acidic mi-
croenvironment occurred. As a result, insulin and VEGF were
released from the particles, known as acid-degradable sense-and-
treat systems. Both of these DDSs were potentially suggested as
Adv. Healthcare Mater. 2020, 9, 2000248 2000248 (12 of 42) © 2020 The Authors. Published by WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim
www.advancedsciencenews.com www.advhealthmat.de
Figure 3. A) Schematic illustration of the o-NBA-RFP@ZIF-8 synthesis and in the application of the DDS in the light-controlled synergistic antibacterial
therapy to inhibit bacteria-induced wound infection. B) a) TEM images of o-NBA-RFP@ZIF-8 NPs treated with UV irradiation at different exposure times
of a1 = 15, a2 = 60, and a3 = 120 min. C) The release of RFP; D) pH change; and E) Zn2+ ion release at different time periods and conditions. F)
Panels (i) and (ii) refer to ampicillin-resistant E. coli and MRSA, respectively, treated at different conditions of: 1) PBS + UV-light, 2) ZIF-8 + UV-light,
3) o-NBA@ZIF-8 + dark, 4) o-NBA@ZIF-8 + UV-light, 5) RFP@ZIF-8 + UV-light, 6) o-NBA- RFP@ZIF-8 + dark, and 7) o-NBA-RFP @ZIF-8 + UV-light.
G) Photographs of infected wound infected by MRSA 1) PBS + UV-light, 2) ZIF-8 + UV-light, 3) o-NBA@ZIF-8 + dark, 4) o-NBA@ZIF-8 + UV-light, 5)
RFP@ZIF-8 +UV-light, 6) o-NBA-RFP@ZIF-8 + dark, 7) o-NBA-RFP@ZIF-8 +UV-light, and 8) healthy mice. i) 0 day, ii) 1 day, and iii) 3 day. Reproduced
with permission.[26] Copyright 2018, Wiley-VCH.
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Figure 4. A) Schematic illustration of the IG@ZIF-8 synthesis and the pH degradable property of the nanosystem triggered by glucose through the
encapsulated GOx. B) Confocal laser scanning microscopy images of the FITC-labeled insulin- and coumarin-modified GOx-loaded ZIF-8 (I and II,
respectively) and the bright field and merged image of the developed DDS (III and IV, respectively). C) SEM images of I) the insulin and GOx-loaded
ZIF-8, II) glucose-treated insulin/GOx-loaded ZIF-8 for 1 h, and III) treatment of the DDS with a buffer solution pH 7.4 for two days. D) Glucose
concentration-dependent release study of the IG@ZIF-8 at different concentrations of glucose: a) 0, b) 1 × 10−3 m, c) 5 × 10−3 m, d) 10 × 10−3 m, e)
50 × 10−3 m for 1 h. E) The release study of FITC-labeled insulin from the IG@ZIF-8 in the presence of different carbohydrates, including a) glucose
(50 × 10−3 m), b) galactose (50 × 10−3 m), c) 𝛽-lactose (50 × 10−3 m), d) sucrose (50 × 10−3 m), and e) pure buffer solution, for 1 h. F) Switchable
release of insulin from the IG@ZIF-8 in the presence of high (15 × 10−3 m, blue) and low (5 × 10−3 m, yellow) concentration of glucose. Reproduced
with permission.[39] Copyright 2012, American Chemical Society.
“intelligent” carriers for the therapy of diabetes and macular dis-
ease, respectively. In the case of controlled release of insulin from
the insulin and GOx-coloaded ZIF-8 (IG@ZIF-8) NPs, loading of
the two cargos was performed in a one-pot method, as shown in
Figure 4A. Glucose acted as a key player to control the local pH
at the nanoenvironment of the IG@ZIF-8 NPs. In fact, the local
acidic nanoenvironment created by the conversion of glucose to
gluconic acid via the biocatalytic effect of GOx led to the degrada-
tion of the IG@ZIF-8 and, in turn, induced the release of insulin.
In the confocal laser scanning microscopy images of the ZIF-8
NPs loaded with FITC-labeled insulin (green) and the coumarin-
functionalized GOx (blue) (Figure 4B, panel I and panel II, re-
spectively), the overlapped turquoise color was related to the in-
ternal integration of the two cargos in the ZIF-8 NPs (Figure 4B,
panel IV), confirming the successful co-immobilization of the
proteins within the porous ZIF. Scanning electron microscope
(SEM) image of the IG@ZIF-8 NPs with rhombic dodecahedral
shape and particle size of ≈300−350 nm, are shown in Figure 4C
panel (I). This morphology was retained when the IG@ZIF-8
NPs were treated with the buffer solution without glucose (Fig-
ure 4C, panel III). Interestingly, after treatment with glucose so-
lution (50 × 10−3 m), the corrosion of the protein-loaded ZIF-8
occurred, proving the degradation of the IG@ZIF-8 due to lo-
cal acidic nanoenvironment, generated by the GOx-mediated ox-
idation of glucose (Figure 4C, panel II). Release study of FITC-
labeled insulin from the IG@ZIF-8 showed that when the con-
centration of glucose increased, the release of the insulin was ac-
celerated for a fixed time of 1 h, again confirming the glucose-
dependent degradation of the IG@ZIF-8 to control the insulin
release (Figure 4D). In addition, among different saccharides,
only glucose triggered the release of insulin from the IG@ZIF-
8 (Figure 4E). A switchable ON/OFF release of insulin was also
observedwhen an increase/decrease of the glucose concentration
was applied (Figure 4F). All these observations clearly proved that
the intelligent controlled DDS of insulin could potentially be de-
veloped for the treatment of diabetes. The same results were ob-
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tained when VEGF aptamer and GOx were encapsulated within
ZIF-8 (VG-ZIF-8). The authors showed that the release of VEGF
aptamer was glucose-dependent in the VG-ZIF-8 NPs, which was
consistent with the increased local acidity at the aptamer-loaded
ZIF-8 due to the GOx-catalyzed conversion of glucose to gluconic
acid, and thus, degradation of ZIF-8 matrix and accelerated re-
lease of the VEGF aptamer. These results hold a great promise for
the potential application of the VG-ZIF-8 as an “intelligent” sys-
tem for the inhibition of VEGF-induced angiogenesis in macular
disease.[39] Recently, GOx and hemoglobin encapsulated-ZIF-8
NPs were prepared in which GOx and hemoglobin acted as nutri-
ent starvation and radical generation agents respectively, endow-
ing the nanosystem anti-cancer property in vitro.[171] Although
great results were obtained in the in vitro phase of this study, the
in vivo studies in animal models were missing and seems to be
imperative in future studies with similar concept.
Cell membrane coating nanotechnology has emerged as a
promising approach to facilitate the delivery of therapeutic agents
through the camouflagation of NPs within a layer of a specific
cell membrane. Utilizing such bio-inspired technology could
enhance the colloidal stability of theNPs andminimize their non-
specific tissue accumulation.[172,173] Using distinctive advantages
of neutrophils, including inflammation targeting ability and
antitumor/antibacterial properties, artificial super neutrophils
were constructed by encapsulating two enzymes, i.e., GOx and
chloroperoxidase (CPO) into ZIF-8 NPs, and further coverage of
neutrophil membrane (NM) on the surface of GOx/CPO-caged
ZIF-8 NPs. It has been shown that the neutrophil-mimicked
nanosystem produced seven-fold higher reactive hypochlorous
acid (HClO) than the natural neutrophils through GOx/CPO-
mediated cascades reactions for eliminating tumors and
infections.[146] The encapsulation of vaccines into MOFs, i.e.,
ovalbumin and attaching the cytosine-phosphate-guanine
oligodeoxynucleotides (CPGO) in/on ZIF-8 (OVA/CPGO-ZIF-
8), was carried out by Quʼs research group.[161] Their results
showed that the OVA/CPGO-ZIF-8 had pH-responsive property,
efficiently enabling the system to release the antigen and CPGO
in the same antigen presenting cells, inducing potent humoral
and cellular immune responses. This study sheds light on pro-
ducing novel/effective MOF-based vaccines against a range of
ailments.
In addition to the embedding of a wide variety of drugs, en-
zymes, proteins, and vaccines, living cells[165] and viruses[164,167]
were used to encapsulate/cage within the ZIF frameworks.[139]
For the first time, biomimetic mineralization of tobacco mo-
saic virus (TMV) using ZIF-8 precursors as a robust MOF for
encasing and protecting the virus against foreign denaturing
environmental stressors was investigated by Gassensmithʼs re-
search group.[167] They showed that discrete rod-shaped TMV-
encapsulated ZIF-8 with good uniformity could be obtained.
They also demonstrated that the metal concentration and lig-
and to metal molar ratio affected distinct morphologies of the
core−shell composites and the size of ZIF-8 NPs, which greatly
influenced the stability of the core–shell hybrid particles.[164] On
the encapsulation of living cells, i.e., yeast, it has been shown that
mechanical constraints imposed by the ZIF-8 coating prohibited
the living cells from reproducing, while cell metabolic processes
were maintained due to the microporous shell of ZIF-8 that al-
lowed the transfer of small molecules like oxygen and glucose
to the cell. Interestingly, this biomimetic mineralization, i.e., the
ZIF-shell, was easily be removed by mildly acidic pH or ethylene-
diaminetetraacetic acid (EDTA), leading to a “switching-OFF” ef-
fect and the recovery of the full functionality of the encapsulated
cells or bio-macromolecules.[143,165]
4. Biomedical Applications of Multifunctional
ZIF-Based Composites
As mentioned in the introduction section, ZIF-based compos-
ites, especially the ones prepared by ZIF-8, have extensively
been applied in many biomedical applications, including can-
cer therapy[22–25] and antimicrobial purposes.[26–28] Neverthe-
less, the poor water disparity of ZIF-8 has limited its advanced
applications.[174] On the other hand, the integration of functional
materials (e.g., metal NPs/nanorods, mesoporous silicas, photo-
sensitizers (PS), light-absorbing dyes, quantum dots, polymers,
graphene, proteins, and enzymes) with ZIFs is a necessity to
combine the merits of both the components, including the flex-
ibility and high porosity of ZIFs with unique imaging, targeting
properties and dispersiblity of functional materials (Scheme 1).
Thus, the unique features of the composites, resulting from the
synergistic combination of both ZIFs and other active compo-
nents, have made them as highly attractive hybrid materials for
many biomedical applications, which are not attainable with an
individual component. Table 2 summarizes the recent biomedi-
cal applications developed by ZIF-based composites. In this sec-
tion, we have classified the applications of ZIF-8 into three cat-
egories of monotherapy, combined therapy, and theranostics ap-
plications, and discuss them in detail.
4.1. Monotherapy by ZIF Nanocomposites
Chemotherapy using nanoscale DDSs is one of themost effective
monotherapeutic approaches in cancer ablation in vivo.[208,209]
As discussed in the previous section, ZIF-8 intrinsically pos-
sess the properties of large surface areas, high porosities, and
well-defined structures, making this material capable of loading
and releasing different chemotherapeutic agents.[21] However, its
small pore size (3.4 Å) and poor dispersity in aqueous solution
have limited its wide application in chemotherapy. Therefore,
many attempts have been made on the design and fabrication
of hybrid structures to overcome these problems.[21] Thorough a
facile and simple method, polyacrylic acid@ZIF-8 (PAA@ZIF-8)
NPs were fabricated by Ren et al.[37] with ultrahigh DOX loading
capability (1.9 g of DOX g−1 composite), successfully employed
as a pH-dependent DDS in cancer treatment in vitro. As shown
in Figure 5A, PAA@ZIF-8 composite was prepared by ion-
exchange between Zn2+ and Na+ on the surface of poly(acrylic
acid sodium salt) (PAAS) NPs followed by dropping the resul-
tant NPs into a methanol solution of 2-MeIm to form the hybrid
PAA@ZIF-8 nanostructure, showing an particle size of 128 nm
measured by SEM (Figure 5B). The NPs were highly dispersed
in serum and water with no obvious aggregation, confirm-
ing their good stability and dispersity. As a result of the pH-
dependent degradability of the nanosystem, a faster drug re-
lease rate was observed in acidic medium (pH 5.5) rather than
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Table 2. Summary of multifunctional ZIF-based nanocomposites for diverse applications.
Type of composite and
surface ligand
Encapsulated
Cargo
Size [nm/µm] and
Zeta potential
[mV]
Imaging modality Cells and animal models Main conclusion Ref
PAA@ZIF-8 DOX Before loading:
128 nm; ND
– In vitro: Epithelial MCF-7
breast cancer cells
– PAA@ZIF-8 NPs exhibited pH-sensitive
DOX release property and ultrahigh
loading capacity.
– Drug release from the DOX-loaded
PAA@ZIF-8 NPs was much faster in an
acidic environment (pH 5.5) than at
neutral pH 7.4.
– The MTT assay showed that the
nanocomposite was nearly nontoxic to
live cells.
[37]
FA-BSA-modified
CuS@ZIF-8
QT After loading:
45.1 ± 15.0 nm;
−27.9± 6.0 mV
NIR-FI In vitro: B16F10 melanoma
cells
In vivo: B16F10 melanoma
model
– The FA-BSA-modified nanocomposite
was successfully utilized for overcoming
the drawbacks of QT, including poor
bioavailability and low water solubility, as
well as synergistic combination of
chemotherapy and PTT of cancer in vitro
and in vivo.
[175]
CuS@ZIF-8 DOX Before loading:
125 nm; ND
ITI In vitro: Epithelial MCF-7
breast cancer cells
In vivo: Epithelial MCF-7
breast cancer model
– For the first time, it was demonstrated
that the ZIF-8 network could be
disintegrated at pH 7.4 upon NIR
irradiation.
– DOX-loaded CuS@ZIF-8
nanocomposites was successfully used in
synergistic CPTT of cancer both in vitro
and in vivo.
[176]
ZIF-8-PAAS DOX Before loading:
30–200 nm; ND
In vitro: HeLa cell line
In vivo: Mammary gland
4T1 model
– Different sizes of ZIF-8-PAAS
nanocomposites, ranging from 30 to
200 nm were constructed, while keeping
their crystallinity and pH sensitivity.
– Compared to free DOX, DOX-loaded and
PEG functionalized ZIF-8-PAAS greatly
enhanced cancer chemotherapy both in
vitro and in vivo.
– After PEG functionalization and DOX
loading of the nanosystem,
biodistribution studies showed that DOX
could be effectively delivered to the tumor
area within 24 h. After 48 h, the
fluorescence intensity of DOX in the
tumor site further increased, while the
fluorescence intensities in major organs,
including spleen, lung heart, liver, and
kidney, started to decrease.
[34]
ZnPc@ZIF-8 – 255 nm; + 26 mV FI In vitro: Epithelial HepG-2
cell line
– Excellent photodynamic activity for
cancer treatment was observed using the
ZnPc@ZIF-8 nanocomposite in vitro.
– ZnPc@ZIF-8 was completely degraded
after PDT.
[177]
ZnPc-COOH@ZIF-8 – 97.2 nm; ND – In vitro: Epithelial HepG-2
cell line
– The ZnPc-COOH@ZIF-8 NPs showed
high singlet oxygen quantum yield and
intracellular ROS generation.
– Cell viability demonstrated good
anticancer efficacy of the NPs with low
IC50 values (4.2–4.9 µg mL−1) under
laser light irradiation.
[178]
(Continued)
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Table 2. Continued.
Type of composite and
surface ligand
Encapsulated
Cargo
Size [nm/µm] and
Zeta potential
[mV]
Imaging modality Cells and animal models Main conclusion Ref
Fe3O4@ZIF-8 – 120 nm; −25.7 mV MRI In vitro: Endothelial
HUVEC and epithelial
4T1 cells
In vivo: Mammary gland
4T1 model
– Very high contrast for tumor detection. [31]
RSA-conjugated
Fe3O4@ZIF-90
5-FU Before loading:
90 nm; −18 mV
MRI ND – Remarkable 5-FU release from the
RSA-conjugated Fe3O4@ZIF-90 NPs was
realized under extremely low frequency
alternating magnetic field.
– The nanocomposite served as an effective
MRI contrast tracer for potential
visualization of drug delivery, paving way
for precise construction of DDSs under
MRI surveillance.
[179]
g-C3N4@ZIF-8 DOX Before loading:
60 nm; +31.9 mV
After loading:
≈60 nm; ND
FI In vitro:
Epithelial A549 cell
– The C3N4@ZIF-8 NPs exhibited good
biocompatibility and generated singlet
oxygen efficiently.
– The DOX-loaded g-C3N4@ZIF-8 NPs
were successfully utilized in dual-color
fluorescence imaging-guided
photo-chemo therapy of tumor cells in
vitro.
[180]
MSN-COOH@ZIF-8 Bcl-2 siRNA
and DOX
Before loading:
≈80 nm; + 31.12
± 2.13 mV
– In vitro:
Epithelial MCF-7/ADR and
epithelial SKOV-3/ADR
cells
– The thin film on the surface of
DOX-loaded MSN-COOH had three
functions:
– It acted as a pore blocker to prevent
premature release of DOX.
– It converted the charge of
MSN-COOH from negative to positive
to improve the efficient adsorption of
the siRNA via electrostatic interactions
and its protection from nuclease
degradation.
– It was decomposed in the acidic
endo-lysosome and led to the
intracellular release of the siRNA and
DOX, paving an efficient way to
overcome MDR cancer cells in vitro.
[35]
ZnO@ZIF-8 DOX After loading:
270 nm; ≈−2 mV
– In vitro: HeLa cell line – The mesoporous ZnO core acted as a
DOX storage reservoir and ZIF-8 shell
served as pore blocker to prevent
premature release of DOX at the
physiological environment.
– Significant cytotoxicity of the DOX-loaded
ZnO@ZIF-8 was attributed to synergistic
ROS production of the ZnO@ZIF-8
carrier, generated in acidic condition, and
the chemotherapeutic effect of the
released DOX.
[181]
PEG-modified
Mn-Zn-ZIF-8
– ≈250 nm; ND FI
MRI
In vitro: Epithelial 4T1 cells – The bimetallic Mn-Zn-ZIF composite
showed pH-responsive T1-weighted MRI
contrast effect.
[182]
PANI@ZIF-8 5-FU Before loading:
200 nm; ND
– In vitro: Epithelial MCF-7
breast cancer cells
– The 5-FU-loaded PANI@ZIF-8 exhibited
excellent CPTT effect against breast
cancer cells in vitro.
[183]
(Continued)
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Table 2. Continued.
Type of composite and
surface ligand
Encapsulated
Cargo
Size [nm/µm] and
Zeta potential
[mV]
Imaging modality Cells and animal models Main conclusion Ref
Poloxamer
188-modified ZIF-8
NaClO Before loading:
140.1 ± 6.3 nm;
≈+8.0 mV
After loading:
177.9 ± 13.2 nm;
<+8.0 mV
FI In vitro: Epithelial 4T1 and
fibroblast 3T3 cells
In vivo: mammary gland
4T1 model
– As a proof of concept, concurrent delivery
of ascorbate (as H2O2 generator in the
tumor site) and hypochlorous ion-loaded
poloxamer 188-modified ZIF-8 NPs could
produce ROS at the tumor site, leading to
efficient CDT both in vitro and in vivo
without noticeable side-effects.
– During the treatment, no obvious body
weight loss of mice was observed,
confirming no serious systemic toxicity in
spite of nonspecific biodistribution of the
nanosystem to healthy organs.
[184]
GQD@ZIF-8 DOX Before loading:
50–100 nm; ND
After loading:
50–100 nm; ND
– In vitro: Epithelial 4T1 cells – The embedded GQD NPs could efficiently
convert NIR irradiation into heat.
– Compared to chemotherapy and PTT
alone, synergistic CPTT strategy
significantly killed breast cancer 4T1 cells
in vitro.
[185]
PEG-PUSeSe-
PEG@ZIF-8
DOX After loading:
200 nm; ND
– In vitro: Epithelial
MDA-MB-231 cells
– DOX-loaded PEG-PUSeSe-PEG@ZIF-8
could successfully release the
encapsulated drug in the presence of
external redox agents and acidic
environment in vitro.
[186]
HA-modified
IR820@ZIF-8
Cytarabine After loading:
132.0 ± 9.5 nm;
ND
FI
ITI
In vitro: Epithelial 4T1 cells
In vivo: Mammary gland
4T1 model
– Indocyanine green (IR820) was employed
to conjugate with cytarabine for the
formation of a prodrug in order to
increase drug loading.
– A successful fluorescence
imaging-guided CPTT was realized
through a pH-responsive release behavior
in vitro and in vivo.
– Biodistribution studies showed that the
HA-modified IR820@ZIF-8 can
accumulate at the tumor area within 1 h
post-administration, which was faster
than the nonmodified NPs. The
HA-modified nanosystem kept high
concentration at tumors during 24 h.
[187]
PDA-PCM@ZIF-8 DOX After loading:
130 nm; −5.1 mV
ITI In vitro: Epithelial HepG2
cells
In vivo:
Hepatocellular carcinoma
model
– The biocompatibility of ZIF-8 was greatly
improved by PDA modification.
– The PDA, as a photothermal agent,
caused thermal response switch of phase
change materials for NIR-controlled DOX
release.
– Compared to chemotherapy or PTT alone,
a remarkable anti-tumor effect was
observed using synergistic
thermo-chemotherapy method.
[22]
PDA-MSN@ZIF-8 DOX and
CCM
Before loading:
≈100 nm;
+28.7 ± 1.1 mV
– In vitro: Epithelial
MCF-7/ADR cancer cells
– The CCM and DOX were successfully
loaded within the ZIF shell and PDA-MSN
core, respectively.
– CCM was released upon ZIF-8 shell
degradation which had a strong effect on
the inhibition of p-gp, and, subsequently,
the sustained release of DOX from
PDA-MSN core caused efficient
therapeutic function, potentially opening
new ways for reversing the MDR of
cancer cells.
[188]
(Continued)
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Table 2. Continued.
Type of composite and
surface ligand
Encapsulated
Cargo
Size [nm/µm] and
Zeta potential
[mV]
Imaging modality Cells and animal models Main conclusion Ref
ZIF-8@PDA CCM After loading:
350 nm; −25.4 mV
ITI
PAI
In vitro: Epithelial MCF-7
breast cancer cells and
HeLa cell line
In vivo: Cervical cancer
HeLa model
– The 2D nanosheets of ZIF-8@PDA
structures exhibited ultrahigh CCM
loading content (59.6%) and excellent
stability in water.
– Efficient and precise CPTT of cancer was
accomplished in vitro and in vivo.
[189]
PDA@ZIF-8 MB and
catalase
After loading:
≈100 nm; +
13.2 mV
ITI In vitro: HeLa cell line
In vivo: Cervical cancer
HeLa model
– Successful synergistic PDT and PTT was
implemented for effective anti-cancer
treatment in vitro and in vivo.
– The study demonstrated improved PDT
through catalase enhanced self-sufficient
O2 generation and ROS production with
the aid of MB as photosensitizer.
– PDA acted as a photothermal agent for
PTT.
[190]
Galactose-modified
ZIF-8@WP6
DOX After loading:
203.5 nm; ND
– In vitro: Epithelial HepG2
cells
– DOX-loaded galactose-modified
ZIF-8@WP6 exhibited excellent
pH-sensitive drug release behavior and
water dispersibility.
– Cell cytotoxicity studies confirmed that
the DOX-loaded NPs had selective
toxicity for hepatoma cancer cells.
[174]
HMS@ZIF-8 DOX After loading:
≈700 nm; +31.2
mV
– In vitro: Epithelial MCF-7
breast cancer cells
– Compared to free DOX, the DOX-loaded
HMS@ZIF-8 NPs showed much higher
cytotoxicity against MCF-7 cells.
– The drug was not released under the
physiological environment (pH 7.4) and
released at acidic condition (pH 4–6)
from the carrier.
[191]
HMS@ZIF-8 DOX Before loading:
≈350 nm; ND
– In vitro: Human
hepatocarcinoma
SMMC-7721 cells
– ZIF-8 acted as both a self-sacrificial
template to prepare monodisperse and
size-controllable HMS and as a pore
blocker to construct a pH-responsive
DDS.
– Remarkable efficiency in the killing of
cancer cells was observed by the
DOX-loaded HMS@ZIF-8
[192]
C-dots@ZIF-8 5-FU Before loading:
110 nm; +10.9 mV
FI In vitro: HeLa cell line – The particle size and fluorescence
intensity of C-dots@ZIF-8 NPs was
tunable.
– The NPs not only acted as a
pH-responsive drug carrier but also used
as a fluorescence imaging agent.
[61]
AuNR@ ZIF-8 DOX Before loading:
140 nm; ND
ITI In vitro: Epithelial 4T1 cells
In vivo: Mammary gland
4T1 model
– High DOX loading capacity and pH/NIR
light-responsive DOX release occurred by
the AuNR@ ZIF-8 drug carriers.
– Effective synergistic CPTT was
implemented both in vitro and in vivo.
[60]
PVP-modified Au@
ZIF-8
Ce6 After loading:
106 ± 7.3; ND
– In vitro: Epithelial EMT-6
cells
In vivo:
Epithelial EMT-6 breast
cancer model
– Highly efficient PDT was achieved using
the Ce6-loaded PVP-modified Au@ ZIF-8
in vivo.
– AuNPs acted as nanozyme to catalyze
H2O2 to generate O2 for alleviating tumor
hypoxia. The in situ generated O2 boosted
the production of 1O2 through the PDT
route under irradiation to kill tumor cells.
[193]
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Table 2. Continued.
Type of composite and
surface ligand
Encapsulated
Cargo
Size [nm/µm] and
Zeta potential
[mV]
Imaging modality Cells and animal models Main conclusion Ref
HA-modified
ZIF-8-Fe-PDA
DOX After loading:
≈150 nm; −30.2
mV
MRI Prostatic PC-3 epithelial
and L929 fibroblast cell
lines
– Compared to free DOX, DOX-loaded
HA-modified ZIF-8-Fe-PDA showed
enhanced chemotherapeutic efficacy due
to targeting ability of the NPs toward
CD44 overexpressed PC-3 cells, which
improved intracellular uptake of the DDS
and increased their killing effect on the
cells.
[194]
ZIF-8/GO FES After loading:
50–100 nm; ND
ITI In vitro: Epithelial 4T1 cells – Upon NIR irradiation (808 nm),
FES-loaded ZIF-8/GO NPs had an
excellent PTT effect to kill cancer cells in
vitro.
– The FES-loaded NPs showed negligible
cytotoxicity against 4T1 cells.
[195]
Polyoxometallate@
ZIF-8
5-FU and MB – – ND – Three ZIF-based nanocomposites were
constructed by H3PW12O40, H4SiW12O40
and H3PMo12O40 polyoxometallates
using a simple one-pot method.
– MB and 5-FU-loaded H3PW12O40 @ZIF-8
showed 80% cargo release over 32 days
and 93% cargo release over 50 h for MB
and 5-FU, respectively, in a simulated
body fluid.
[196]
Fe3O4@PAA/AuNCs/
ZIF-8
DOX Before loading:
130 nm; ND
MRI
CT
FI
In vitro: Epithelial HepG2
cells
In vivo: Hepatocarcinoma
H-22 model
– The Fe3O4@PAA/AuNCs/ZIF-8 NPs were
biocompatible and possessed an
ultrahigh loading capacity for DOX
(1.54 g DOX g−1 NPs).
– Simultaneous DOX delivery and trimodal
(CT, MR, and fluorescence) imaging was
achieved by the NPs in vitro and in vivo.
– DOX-loaded NPs suppressed tumor
growth effectively via the EPR effect.
[23]
CaO2@ZIF-67 DOX After loading:
200 nm; +30.1 mV
PAI In vitro: Epithelial MCF-7
breast cancer cells
In vivo:
Epithelial MCF-7 breast
cancer model
– Excellent chemo/chemodynamic therapy
of tumors was achieved by
CaO2@DOX@ZIF-67 NPs in vitro and in
vivo.
– In the acidic TME, the DDS was degraded
to rapidly release DOX and the Co2+ (as
Fenton-like catalyst). Then, the exposed
CaO2 reacted with H2O to
simultaneously generate O2 and H2O2, to
relieve the hypoxia in TME and to
produce ROS through the Fenton
reaction of Co2+ and H2O2.
[197]
Catalase-modified
UCNPs@ZIF-8
MB ND FI In vitro:
Epithelial PL45 cells
– The UCNPs/MB@ZIF-8@catalase
nanocomposite acted as an efficient
NIR/H2O2-responsive PDT agent against
hypoxic tumor cells.
[198]
Si-Gd@PDMAEMA and
PEG-FA-modified
ZIF-8
DOX and Ce6 After loading:
70 nm; ≈ +5 mV
FI
MRI
In vitro: Epithelial MCF-7
breast cancer cells and
epithelial A549 cell
In vivo:
Epithelial MCF-7 breast
cancer model
– In the nanocomposite, Si-Gd NPs and
Ce6 were used for MRI and FI,
respectively. Also, Ce6 was utilized as a
PDT agent. In addition, due to the
pH-responsive capability of PDMAEMA,
it effectively prevented DOX leakage.
– Excellent CPDT was obtained by the DOX
and Ce6-loaded Si-Gd@PDMAEMA and
PEG-FA-modified ZIF-8 guided by the
dual-modal imaging in vivo.
[199]
(Continued)
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Table 2. Continued.
Type of composite and
surface ligand
Encapsulated
Cargo
Size [nm/µm] and
Zeta potential
[mV]
Imaging modality Cells and animal models Main conclusion Ref
PEGFA-modified
UC@mSiO2-
RB@ZIF-90
DOX, RB,
and O2
ND Upconversion and
MRI
In vitro: HeLa and
epithelial 4T1 cells
In vivo: Hepatocarcinoma
H-22 model
– ZIFs were used as an O2 carrier to
overcome tumor hypoxia.
– Successful CPDT was achieved using
DOX, RB, and O2-loaded PEGFA-modified
UC@mSiO2-RB@ZIF-90 nanosystem
through degradation of the outmost
ZIF-90 shell under acidic condition, which
accelerated the release of O2 and DOX in
the acidic TME to overcome tumor
hypoxia and improve chemotherapy.
[200]
FA-modified
UCNPs@ZIF-8
5-FU Before loading:
≈200 nm; ND
FI In vitro: HeLa cell line – Due to the folate receptor-mediated
endocytosis, the 5-FU-loaded FA-modified
UCNPs@ZIF-8 DDS exhibited greater
cytotoxicity against HeLa cells in vitro.
– The FA-modified UCNPs@ZIF-8
nanocomposite not only used as a
targeted anticancer drug carrier but also
acted as a cellular imaging agent.
[201]
Fe3O4@carbon@ ZIF-8 DOX Before loading:
220 nm; ND
FI
MRI
In vitro: Epithelial A549 cell
In vivo
Lung A549 cell model
– The Fe3O4@carbon@ ZIF-8 NPs
exhibited good biocompatibility, high
drug loading content, pH-triggered drug
release behavior as a DDS, and effective
cellular uptake in vitro.
– Compared to the free drug of DOX,
remarkable inhibition of tumor growth
was observed by the DOX-loaded NPs in
vivo.
[202]
CoFe2O4@PDA@ZIF-8 DOX and
CPT
Before loading:
150 nm; ND
MRI
ITI
In vitro: Epithelial HepG2
cells
In vivo: liver HepG2 cell
model
– Compared to the single-drug
chemotherapy system, the DOX and
CPT-loaded DDS improved tumor
therapeutic efficiency significantly.
– PTT and accelerated drug-release were
achieved using NIR irradiation.
– Successful T2-weighted MR
imaging-guided synergistic PTT and
multidrug chemotherapy were achieved
in vitro and in vivo.
[203]
ZGGO@ZIF-8 DOX Before loading:
100–200 nm; ND
Autofluorescence-
free NIR PersL
imaging
In vitro: Epithelial 4T1 cells
In vivo: Mammary gland
4T1 cells model
– The DOX-loaded ZGGO@ZIF-8 DDS
possessed pH-responsive drug delivery
behavior and the autofluorescence-free
NIR PersL imaging capability, thus
causing long-term PersL imaging without
autofluorescence and effective tumor
suppression in vivo.
– Strong PersL signals of the NPs were
found in the lung and liver, while weak
signals were found in the kidney, spleen,
and stomach.
[204]
Pd-Au@ZIF-8 DOX Before loading:
253.7 nm; +
6.15 mV
– In vitro: SMMC-7721 cell – The Pd@Au core could effectively convert
NIR laser into heat, causing not only
accelerating the DOX release from
Pd-Au@ZIF-8 NPs, but also synergistic
CPTT in vitro.
[36]
(Continued)
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Table 2. Continued.
Type of composite and
surface ligand
Encapsulated
Cargo
Size [nm/µm] and
Zeta potential
[mV]
Imaging modality Cells and animal models Main conclusion Ref
ZIF-8@MPN GOx Before loading:
≈150 nm;
≈−16 mV
After loading:
≈170 nm; −17.9
mV
MRI, FI In vitro: Epithelial 4T1 cells
In vivo: Mammary gland
4T1 cells model
– Synergistic CDT and starvation therapy
was implemented by the ATP-responsive
GOx@ZIF@MPN nanosystem to
suppress tumor growth in vivo.
– GOx reacted with the endogenous
glucose in the TME to increase H2O2
concentration for Fenton reaction.
– The released TA from the MPN
degradation accelerated the conversion of
Fe(III) into Fe(II) to generate ROS
through the Fenton reaction of H2O2 and
Fe(II).
[25]
ZIF-8@ZrO2@IL DOX – CT
FLIRI
In vitro: Hepatoma H22
cells
– The DOX-loaded ZIF-8@ZrO2@IL DDS
exhibited effective chemo-microwave
thermal tumor therapy.
– The biocompatibility of ZIF-8 NPs was
significantly improved by ZrO2
modification and the ZrO2 served as an
excellent CT contrast agent.
– IL acted as microwave hyperthermia
agent.
[205]
ZnO@ZIF-8 – ND – In vitro: Antimicrobial
effects of the composite
on the E. coli, P. mirabilis,
S. aureus, and K.
pneumonia
microorganisms
– The ZnO@ZIF-8 composite was used as
an antimicrobial additive in antimicrobial
catheters to kill bacterial cells on the
surface of the medical silicone devices. It
showed promising anti-biofilm effect as
well.
[206]
HMS@ZIF-8 GM After loading:
50–200 nm; +30.1
mV
– In vitro: Cellosaurus
HEI-OC1 cells
– The GM-loaded HMS@ZIF showed a
good cellular uptake in HEI-OC1 cells and
good biocompatibility.
– GM was released within 10 h under acidic
conditions, and thus, the DDS was
introduced for the therapy of Ménière’s
disease.
[207]
CdSNPs@ZIF-8 – ≈230 nm; ND – In vitro: Bactericidal effects
of the NPs on the S.
aureus, and GFP E. coli
microorganisms
– Compared to ZIF-8 and CdSNPs alone,
the CdSNPs@ZIF-8 NPs exhibited
significant antibacterial activity against
both GFP E. coli and S. aureus, confirming
synergetic bactericidal effects of the
nanocomposite.
[28]
Abbreviations: AgNPs: silver NPs; AlgDA: dopamine-modified alginate; Aln: amine-containing alendronate; AuNCs: Au nanoclusters; AuNR: gold nanorod; BSA: bovine serum
albumin; C-dots: fluorescent carbon nanodots; Ce6: chlorin e6; CPDT: chemo-photodynamic therapy; CpG: cytosine phosphate-guanine; CPTT: chemo-photothermal therapy;
CT: computed X-ray tomography; EGCG: epigallocatechin-3-gallate; FLIR: forward-looking infrared; FLIRI: forward-looking infrared imaging; FI: fluorescent imaging; GFP E.
coli: green fluorescent protein-expressing E. coli; GM: gentamicin; GQD: graphene quantum dots; HEI-OC1: House Ear Institute-Organ of Corti 1; HMS: hollow mesoporous
silica; HUVEC: human umbilical vein endothelial cell; IL: ionic liquid; IR820: indocyanine green; ITI: infrared thermal imaging; K. pneumonia: Klebsiella pneumoniae; MPN:metal
polyphenol network; MRI: magnetic resonance imaging; NIR-FI: near-infrared (NIR) fluorescent imaging; P. mirabilis: Proteus mirabilis; PAA: polyacrylic acid; PAAS: poly(acrylic
acid sodium salt); PAI: photoacoustic imaging; PANI: polyaniline; PDA: polydopamine; PDMAEMA: poly(2- (diethylamino)ethyl methacrylate); PEGFA: NH2-poly(ethylene
glycol)-modified FA; PEG-FA: folic acidpolyethylene glycol- maleimide; PEG-PUSeSe-PEG: polyethylene glycol-dialkyl diselenide containing polyurethane-polyethylene glycol;
PersL: persistent luminescence; PMA: poly[isobutylene–alt–maleic anhydride]–graft–dodecyl; PpIX: protoporphyrin IX; QT: quercetin; RB: Rose Bengal; RSA: rat serum albumin;
SERS: surface enhanced Raman spectroscopy; Si-Gd: Gd doped silicon; SiRNA: small interfering RNAs; UCNPs: upconversion NPs; WP6: carboxylated pillar[6]arene; ZnPc:
zinc(II) phthalocyanine.
at the neutral pH of 7.4 after 60 h (Figure 5C). The 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) (MTT)
cell assay on MCF-7 cells showed that DOX-loaded PAA@ZIF-
8 composite had similar toxicity with the free drug at differ-
ent loadings. The results also confirmed that the PAA@ZIF-8
NPs were nearly nontoxic to live cells, proving the bio-
compatibility of the NPs (Figure 5D). Although excellent re-
sults were obtained in vitro, the assessment of the developed
NPs in vivo was not performed to identify its translational
potential.
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Figure 5. A) Schematic depiction of preparing PAA@ZIF-8 composite as a drug vehicle for loading and pH-controlled release of DOX. B) SEM image of
PAA@ZIF-8. C) The release behavior of DOX at pH 5.5 and 7.4 at 37 °C from DOX-loaded PAA@ZIF-8 NPs. D) Cytotoxicity assessment of MCF-7 cells
using different concentrations of PAA@ZIF-8 NPs, DOX-loaded PAA@ZIF-8 NPs and free DOX for 24 h. Reproduced with permission.[37] Copyright
2014, The Royal Society of Chemistry.
In 2017, the same nanocomposite was prepared by Yan et al.[34]
and successfully applied as vectors to deliver DOX for anticancer
therapy in mice model, greatly enhancing drug therapeutic ef-
ficacy. Toxicity assessments, including hematoxylin and eosin
staining analysis on tumor and major organs, blood chemistry
tests, and hematology analysis, confirmed that the nanocompos-
ites were highly biocompatible.
As mentioned in the sections above, the MDR is one of the
major challenges in the treatment of cancer chemotherapy. Co-
delivering chemotherapeutic drugs and MDR gene silencing
siRNAs paves a rational and effective way to circumvent theMDR
shortcomings in conventional cancer chemotherapy.[210–212] In
2018, Pan et al.[35] in situ synthesized an ultrathin ZIF-8 film on
carboxylated mesoporous silica (MSN-COOH) surface and pre-
pared a novel DDS for dual delivery of siRNAs and DOX. The
mesoporous channels of MSN-COOH acted as a reservoir to load
DOX drug and the positively charged ZIF-8 shell was exploit for
efficient loading of siRNA via electrostatic interactions and, in
turn, protected siRNA from nuclease degradation. The microp-
orous shell also acted as pore blocker to overcome premature re-
lease of DOX from the mesoporous silica channels. In vitro stud-
ies demonstrated that the positively charged ZIF-8 film promoted
the uptake of the dual drug-loaded NPs in MDR cancer cells of
MCF-7/ADR and SKOV-3/ADR. In fact, decomposition of the
ZIF thin layer in the acidic endo-lysosome, and subsequently, the
intracellular release of siRNAs and chemotherapeutic DOX, sig-
nificantly enhanced chemotherapeutic efficacy. Although in vivo
studies were not investigated, this study highlighted the power of
ZIF-8 as a pore blocker of porous materials and an excellent plat-
form to adsorb/control the delivery of siRNAs and its protection
against nuclease degradation.[35]
As a result of the dissolution of ZIF-8 in acidic media and
EDTA, various hollow structures, including hollow TiO2,
[213]
polyphenol-metal networks,[214,215] ZnS nanocages,[216] and
hierarchical-pore MOFs[136] have been successfully synthesized.
Size and morphology-controllable hollow MSNs (HMSN), in-
cluding cubic and dodecahedral morphologies ranging from≈80
to ≈3000 nm in particle size, were fabricated by acid-degradable
ZIF-8 as a self-sacrificial template (Figure 6A).[192] After encap-
sulating the HMSNs with DOX (HMSN@DOX) and subsequent
coating of HMSN@DOX with ZIF-8 layer as pore blocker, the
resulting pH-responsive DDS showed remarkable efficiency in
killing SMMC-7721 cancer cells (human liver cancer cell lines)
(Figure 6B,C).
As above-mentioned, the pore diameter of ZIF-8 is very
small (3.4 Å), which is even smaller than most of the anti-
cancer drugs.[14] Such small pores impede the high drug load-
ing potential of NPs, and subsequently hinder highly efficient
chemotherapy.[100,217] In 2018, Zhao and co-workers[181] con-
structed ZnO@ZIF-8 nanocomposites containing mesoporous
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Figure 6. A) Schematic illustration of a) synthesis of size andmorphology tunable HMSN, employing ZIF-8 as template and b)HMSN@DOX coated ZIF-
8 as pH-responsive DDS. B) DOX release profiles from DOX encapsulated HMSN@ZIF-8 system at different pH values. C) Cell viability of SMMC-7721
cancer cells when incubated with HMSN@ZIF-8 (black), DOX (green), and DOX encapsulated HMSN@ZIF-8 (blue) for 24 h with different concentra-
tions. Reproduced with permission.[192] Copyright 2017, The Royal Society of Chemistry.
ZnO core and ZIF-8 shell. In themesoporous/microporous com-
posite, the ZnO core acted as drug carrier to easily load anti-
cancer drug, DOX, at the mesoporous channels of ZnO core
and the microporous shell served as a cap to prevent prema-
ture release of chemotherapeutic DOX at physiological environ-
ment. In addition, the ZnO core not only functioned as a drug
carrier, but also used as a Zn ion source to create the ZIF-8
shell. The authors showed that more than 80% of the anticancer
drugs were released at the pH value of 5.5. This was mainly at-
tributed to the dissolution of ZnO core and ZIF-8 shell in acidic
conditions, endowing the composite with good pH-responsive
drug release behavior. The MTT assay in HeLa cells showed
that the toxicity of DOX-encapsulated ZnO@ZIF-8 was signif-
icantly higher than that of the composite alone and free DOX,
which was mainly due to the synergistic toxic effect of released
anticancer DOX and ZnO@ZIF-8 decomposition under acidic
TME.[181] A similar approach was reported by Zhou et al.[186] in
which diselenide-containing triblock copolymer (PEG-PUSeSe-
PEG) was employed as a drug carrier and ZIF-8 acted as a gate-
keeper to delay drug release from the copolymer micelles. The
selenium-containing polymers not only served as DOX storage
agent, but also it was disassembled in the presence of redox
agents (H2O2/GSH), which are overproduced in cancer cells.
Although their cancer therapy studies were conducted in vitro,
the design/fabrication of such redox/pH-sensitive nanocompos-
ite with good loading capacity, controllable drug release property
and excellent biocompatibility paved a rational way to fabricate
multiresponsive DDSs in cancer treatment.
As above-mentioned, another limitation of ZIF-8 is the poor
water dispersibility and inaccessibility of its free surface func-
tional groups, preventing its further applications toward ad-
vanced biomedical goals. Therefore, the construction of water-
dispersible targeted ZIF-8 based DDSs is of particular impor-
tance, especially in chemotherapy applications.[102] Macrocyclic
water-soluble carboxylated pillar[6]arene (WP6) was used to func-
tionalize ZIF-8@DOX via the coordination between metal nodes
of the drug-loaded ZIF-8 and the carboxyl group of WP6 to
improve water dispersibility of the DDS.[174] In addition, through
host-guest complexation between theWP6 and a galactose deriva-
tive as targeting ligand, a highly dispersed/targeted DDS was
prepared to increase the anticancer efficiency of ZIF-8@DOX
NPs toward galectin overexpressing hepatoma cancer cells. Con-
focal laser scanning microscope studies and flow cytometry
showed that the pH-responsive DDS took up by HepG2 cells
and DOX were released efficiently within the cells. This study
was a pioneering work on the fabrication of rational targeted pH-
responsive water dispersible drug carriers using the combination
of supramolecular hybrid structures and ZIF-8 for potential can-
cer therapy.
Chemodynamic therapy (CDT) as an emerging and unique
therapeutic strategy has also been recently developed for can-
cer therapy through reactive oxygen species (ROS) generation
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mediated by Fenton reaction.[218] In this process, •OH radicals
can directly be generated by the Fenton reaction of overproduced
endogenous H2O2 and metal ions catalysts, e.g. Fe(II) or Cu(I),
in tumor sites, leading to apoptosis induction and tumor growth
inhibition.[218–220] However, one of the main obstacles of can-
cer CDT is the insufficient concentration of H2O2 in the TME
that causes poor anticancer performance of this technique.[221]
In 2019, the proof-of-concept of singlet oxygen-based CDT for se-
lective tumor eradication using hypochlorous ion (ClO−)-loaded
ZIF-8 was proposed by Zhao co-workers (Figure 7A).[184] ClO−
could react with H2O2 in TME to stoichiometrically generate sin-
glet oxygen and kill cancer cells.[222] On the other hand, the en-
richment of H2O2 in TME was achieved by simultaneous in-
traperitoneal (i.p.) administration of the ascorbate (Asc) to en-
hance the efficiency of CDT. It was shown that Asc could pro-
mote H2O2 accumulation in the extracellular fluids of solid tu-
mors at its pharmacological concentration.[223,224] They showed
combinational ClO− and Asc delivery via intravenous (i.v.) and
i.p. administration, respectively, is a potent CDT system for se-
lective cancer therapy in vivo (Figure 7A). The ClO−-loaded ZIF-
8 (ClO@MOF) was prepared in a one-pot reaction and further
coated with poloxamer 188 (Pluronic F68) to increase the stability
of the nanosystem. The hydrodynamic size of the F68-modified
ClO@MOF (ClO@MOF/F68) NPs was 177.9 ± 13.2 nm (Fig-
ure 7B). As shown in Figure 7C, the prepared NPs exhibited a
slightly positive surface charge. Significant amounts of ROS even
at the absence of Asc was observed in murine mammary carci-
noma 4T1 cells treated by ClO@MOF/F68 NPs (Figure 7D), at-
tributed to the reaction of ClO− with intracellular H2O2. Interest-
ingly, the cells co-treated by ClO@MOF/F68 NPs plus free Asc
generated the highest level of ROS, confirming Asc-mediated el-
evation of intracellular H2O2 level to boost the ROS concentra-
tion. Compared to ClO@MOF/F68 alone, the co-supplement of
ClO@MOF/F68 with Asc remarkably reduced the cell viability
of 4T1 cells due to the enhanced ROS production (Figure 7E). In
addition, significant GSH reduction was observed using the com-
bination of ClO@MOF/F68 and Asc in vitro (Figure 7F). GSH is
amajor antioxidant inside the tumor cells, which hinders the per-
formance of ROS-based nanomedicines to treat cancer. In agree-
ment with the in vitro cytotoxicity experiments, in vivo antitu-
mor studies on 4T1 tumor-bearing xenograft mice showed that
the combinational formulation, i.e., ClO@MOF/F68 plusAsc, ex-
hibited significant anti-tumor activity than the other groups (Fig-
ure 7G). Altogether, this study paves new ways to overcome the
side effects of traditional PDT and sonodynamic therapy (SDT),
including the limited tissue penetration of light in PDT, low
quantum yield of singlet oxygen in SDT, and the toxicity of pho-
tosensitizers/sonosensitizers, to develop effective ROS-based an-
titumor therapy with lower side-effects.
4.2. Combined Therapy by ZIF Nanocomposites
Although monotherapy of cancer by novel DDSs enhances ther-
apeutic efficiency and decreases side effects of toxic chemother-
apeutic drugs, still the MDR of cancer cells in chemotherapy is a
big hurdle, remaining as an important challenge in effective can-
cer treatment.[131,225] Therefore, the construction of multifunc-
tional cancer treatment systems, combining multiple therapeu-
tic modalities, including chemotherapy, PTT and PDT in a sin-
gle system for more effective cancer treatment has been an im-
perative goal.[3,17,21,226–229] Herein, we will discuss about the ZIF-
based multifunctional nanocomposites developed very recently
for combined cancer therapy.
PTT, a light-induced method, is a minimally invasive treat-
ment that employs the photothermal agents located in tumors
to convert NIR energy into heat, leading to irreversible cellular
damage and subsequent tumor killing.[230] Various photother-
mal agents including gold NPs,[231] MXenes,[232,233] bismuth-
containing nanomaterials,[234–236] organic NPs,[237] liquid metal
nanodroplets,[238] and 2D noncarbonaceous materials[239] have
been developed for PTT. Simultaneous chemo-photothermal
therapy (CPTT) can be realized by combining photothermal
agents and chemotherapeutic drugswithinZIFs. Tian et al.[185,195]
developed DOX-encapsulated ZIF-8/graphene quantum dot
(GQD) nanocomposites, utilizing a one-pot method with a par-
ticle size of 50–100 nm, to achieve synergistic photothermal ther-
apy and controlled drug delivery (Figure 8A). Since ZIF-8 is sta-
ble under neutral conditions (pH 7.4) and can disintegrate under
acidic environment, DOX release was much faster at acidic con-
dition than in neutral environment from the DOX@ZIF-8/GQD
(Figure 8B). The drug-loaded NPs efficiently converted NIR irra-
diation into heat, which was attributed to the high photothermal
conversion efficiency and excellent thermal conductivity of GQD
as a photothermal agent (Figure 8C). In vitro studies on the viabil-
ity of 4T1 breast cancer cell line showed a synergistic effect to kill
the cancer cells, owning to the photothermal effect of GQDs and
the pH-dependent DOX release from the multifunctional DDS,
holding great promise for CPTT of cancer (Figure 8D).
Wang et al.,[176] for the first time, demonstrated that copper sul-
fide (CuS)-incorporated ZIF-8 (CuS@ZIF-8) NPs decomposed
under physiological conditions, i.e., pH 7.4, while exposed to NIR
laser irradiation, which was related to the uneven thermal ex-
pansion of ZIF-8. The CuS@ZIF-8 nanosystem was prepared by
PVP-mediated in situ growth of ZIF-8 around the CuS NPs. The
incorporation not only did not alter the low pH-degradability of
ZIF-8 NPs, but also boosted a synergistic chemo-photothermal
therapeutic effect on tumor cells killing after DOX loading into
the CuS@ZIF-8 nanocomposite.
Recently, noble bimetallic nanomaterials have gained great in-
terest as promising photothermal agents owing to the advantages
of facile synthesis, chemical inertness, and high photothermal
conversion efficiency.[240,241] However, their unstable structures
and shapes, and potential biotoxicity have limited their biomed-
ical applications.[242] As a result of the low toxicity of palladium
(Pd) at concentrations required for photothermal therapy, DOX-
loaded Au-Pd bimetallic nanocomposites encapsulated within
ZIF-8 (Au-Pd/DOX@ZIF-8) were used to fabricate a multifunc-
tional DDS for synergistic in vitro CPTT of cancer cells (Fig-
ure 9A).[36] Pd NPs were first prepared and then covered by Au
nanosheets. To obtain Au-Pd/DOX@ZIF-8 nanocomposites, the
Au-Pd NPs and DOX were synchronously encapsulated by ZIF-8
in a single step. The Pd-Au was able to convert NIR light into heat
and accelerate the release of chemotherapeutic DOX through lo-
cal hyperthermia. Furthermore, the ZIF-8 shell was degraded at
acidic tumor microenvironment, leading to the release of encap-
sulated DOX. Such a synergistic scenario introduced a cytotoxic
nanosystem against SMMC-7721 cells, which was not attainable
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Figure 7. A) Schematic illustration of ClO@MOF/F68 synthesis and depiction of singlet oxygen-based CDT through the i.v. delivery of ClO@MOF/F68
NPs plus concurrent i.p. administration of Asc and singlet oxygen production by hypochlorous ion for selective apoptosis. B) Hydrodynamic size and
C) zeta potential of MOF, MOF/F68, ClO@MOF/F68 NPs. D) The intracellular singlet oxygen generation in 4T1 cells treated with the different NPs
using fluorescence intensity measurement. E) Cell viability of 4T1 cells incubated with the NPs. F) The relative GSH level in the 4T1 cells treated by
different NPs. G) Measurement of tumor weight in 4T1 tumor-bearing mice treated with different formulations at the end of treatment. Reproduced with
permission.[184] Copyright 2019, Wiley-VCH.
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Figure 8. A) Schematic illustration of the preparation of DOX@ZIF-8/GQD and synergistic photothermal therapy and DOX delivery. B) DOX release
profiles of DOX@ZIF-8/GQD at different pHs. C) Photothermal effects of DOX@ZIF-8/GQD in water and Dulbecco’s Modified Eagle Medium (DMEM)
at different concentrations employing 808 nm laser irradiation at 1.5 W cm−2. D) Cell viability of 4T1 cells after 8 h of incubation with free DOX, ZIF-
8/GQD, and DOX-ZIF-8/GQD without and with 808 nm laser irradiation. Reproduced with permission.[185] Copyright 2017, American Chemical Society.
via a single modality. Cancer cell viability reached 11% after pre-
treating with Au-Pd/DOX@ZIF-8 (80 µg mL−1) for 24 h under
irradiation of NIR laser for 10 min, which the viability was lower
when no pretreatment was used, confirming the accelerated re-
lease of the encapsulated DOX under laser irradiation.
Although metal-based NIR adsorbing agents have extensively
been utilized for PTT, they are expensive and suffer from
low photostability under long-term laser irradiation.[36,233,243–245]
Organic polymers, such as polyaniline (PANI)[243,246–248] and
polypyrrole[249–252] have good biocompatibility, low cost, highme-
chanical flexibility and strong NIR absorption.[243,249] These fea-
tures endow them with excellent capacities to be exploited as al-
ternative photothermal agents in PTT.[253] In 2018, Silva et al.[183]
synthesized PANI-decorated ZIF-8 NPs (PANI@ZIF-8) and after
5-FU drug loading, this multifunctional DDS was used as an effi-
cient CPTT platform for in vitro cancer therapy (Figure 9B). The
authors showed that the release of 5-FU from the polymer-coated
ZIF-8 reached to 68% at pH 5.2, while at the same condition and
uponNIR laser irradiation (980 nm, 0.8W cm−2), the drug release
was ≈80%. Therefore, the PANI not only accelerated the drug re-
lease, but also served as NIR-light to heat conversion agent to kill
cancer cells.
It has been reported that unmodified ZIF-8 has high toxicity,
which limits its in vivo applications in the design/fabrication of
advanced DDSs.[22,100] Therefore surface modification of ZIF-8 is
an imperative task to tune/improve the biocompatibility of this
carrier. Using cytotoxicity and in vivo acute toxicity assessments,
Wu et al.[22] demonstrated that the biosafety of ZIF-8 NPs was
significantly improved by PDA coating. The PDA also acted as
photothermal agent to achieve PTT. To precisely control the rate
of drug release from the DOX-loaded ZIF-8/PDA NPs, the au-
thors used a phase-change material (PCM), i.e., tetradecanol, for
NIR-mediated drug release. As the melting point of tetradecanol
is 38–40 °C and it does not dissolve under physiological condi-
tions, a more control on DOX release was obtained upon NIR
irradiation via tetradecanol dissolvation by increasing local tem-
perature through light-to-heat conversion effect of PDA. There-
fore, a controlled CPTT was successfully achieved by the biocom-
patible DOX-loaded PDA-PCM@ZIF-8 in vivo. The cytotoxicity
studies in HepG2 cells indicated that the ZIF-8 itself has high
cytotoxicity, while the PDA@ZIF-8 and PDA-PCM@ZIF-8 had
favorable biocompatibility. When 15 mg kg−1 of ZIF-8 was in-
jected to the mouse through the i.v. route, the survival rate was
only 60% and an abnormality was seen in the liver of the mouse
after dissection. In contrast, in the case of PDA@ZIF-8, the sur-
vival rate was 80% for the administration dose of 75 mg kg−1,
again proving increased biocompatibility after surface modifica-
tion.
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Figure 9. A) Schematic illustration of the fabrication of Au-Pd/DOX@ZIF-8 and its application in synergistic CPTT of cancer cells. Reproduced with
permission.[36] Copyright 2017, The Royal Society of Chemistry. B) Schematic application of 5-FU-loaded PANI@ZIF-8 in CPTT. Reproduced with
permission.[183] Copyright 2018, American Chemical Society.
The same group used ZrO2 coating onto the surface of
ZIF-8 NPs to improve the biocompatibility of the NPs.[205]
The ZrO2 shell not only boosted biocompatibility of ZIF-8,
but also served as an excellent CT contrast agent, owning to
the high atomic number of Zr element. In addition to DOX
loading, ionic liquid was also loaded on the surface of ZIF-
8@ ZrO2 for synergistic chemo/microwave thermal therapy of
cancer.
Successful in vitro and in vivo synergistic CPTT was reported
by loading DOX into AuNR coated ZIF-8 (AuNR@ZIF-8-DOX)
NPs, and controlled release under NIR irradiation (Figure 10A).
In this study by Li et al.,[60] the authors showed NIR and pH
dual stimuli-responsive DOX release from AuNR@ZIF-8-DOX
(Figure 10B,C). The core–shell nanostructures significantly
induced photothermal anticancer effect both in vitro and in vivo
(Figure 10D,E). As a result of the high light-to-heat conversion
capability of AuNR, the AuNR@ZIF-8-DOX NPs possessed the
highest toxicity at cellular and animal models as compared to the
single therapeutic treatment approaches, i.e., separate
chemotherapy and PTT. This study introduced the AuNR@ZIF-
8-DOX NPs as a powerful multifunctional DDS for combined
CPTT of cancer.[60]
The combination of CDT and PDT (CPDT) has emerged as
a new strategy for cancer treatment.[200,254–256] However, overex-
pression of GSH and hypoxia in TME are two main obstacles
that severely affect the successful treatment of cancer through
the combined strategies.[257] Recently, O2-Cu/ZIF-8@Ce6/ZIF-
8@F127 nanocomposite was prepared to simultaneously de-
crease hypoxia and GSH level for enhanced CPDT.[258] It is note-
worthy that one of the important features of ZIFs is its gas stor-
age capability.[6] ZIF-90 as a member of ZIFs has been reported
as an O2 carrier to overcome tumor hypoxia for efficient PDT.
[200]
However, in the O2-Cu/ZIF-8@Ce6/ZIF-8@F127 nanocompos-
ite, ZIF-8 acted as O2 carrier and the doped Cu
2+ in the ZIF net-
work doubled the O2 loading capacity of ZIF-8 to increase the
amount of ROS generated by PDT using Ce6 photosensitizer
under 650 nm laser irradiation. Moreover, the released Cu2+ re-
duced GSH through oxidation reaction and the produced byprod-
uct, i.e., Cu+ acted as CDT agent and generates cytotoxic •OH
via Fenton-like reaction by reacting with H2O2, which was over-
expressed in tumor cells.[259,260]
In addition to cancer therapy, ZIF-mediated combined ther-
apy has been proposed for other diseases.[26,261,262] For exam-
ple, endophthalmitis is a disease that occurs in many intraocu-
lar surgeries, particularly cataract surgery due to the localization
of the pathogenic microorganisms in the damaged tissue. This
infection leads commonly to intraocular inflammation, uveitis,
and damage to the vitreous cavity within the eyeball.[263,264] Re-
cently, the combination of chemotherapy and PDT was used for
successful inhibition of infectious endophthalmitis by ZIFs.[262]
To this end, ammonium methylbenzene blue (MB)-loaded ZIF-
8-PAA (ZPM) was first prepared, followed by AgNPs incorpo-
ration, using dopamine as reducing agent and then further
modification with Van/NH2-PEG to give NIR and pH-responsive
ZIF-8-PAA-MB@AgNPs@Van-PEG (ZPMAVP) nanocomposite
for the treatment of bacterial endophthalmitis (Figure 11A). The
MB acted as photosensitizer antibacterial agent and PAA en-
dowed the nanocomposite with higher pH-responsive properties
and better drug loading capacity. The bactericidal and antiadhe-
sive activities of the NPs were investigated by agar plate counting
method and SEM imaging. In the case of ZPMNPs, treating with
three kinds of bacteria, i.e., S. aureus, E. coli, and MRSA, resulted
in no apparent decrease of bacterial growth when laser treatment
was not applied. In contrast, an obvious reduction of bacteria was
observed under laser irradiation at 650 nm, confirming the high
efficiency of the PDT. As a result of the antibacterial property of
AgNPs, the Ag-incorporated-ZPM (ZPMA) showed higher bac-
tericidal effects. It has been reported that Van, which is a highly
efficient antibiotic can act as a targeting molecule, especially to-
wards Gram-positive bacteria.[265] As shown in Figure 11B–D, the
grafting of the targeting molecule and hydrophilic PEG chain on
ZPMA further increased the bacteria-killing efficiency in all three
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Figure 10. A) Schematic illustration of AuNR@ZIF-8-DOX for synergistic cancer CPTT. B) Photothermal heating curves of AuNR@ZIF-8 core–shell
nanostructures at different concentrations of the NPs in PBS solution under NIR laser irradiation (1 W cm−2). C) pH- and NIR-dependent DOX release
profiles from AuNR@ZIF-8-DOX NPs with and without NIR laser irradiation. D) CCK-8 viability assay of 4T1 cells under different treatment conditions.
E) In vivo synergistic chemo-photothermal efficiency of AuNR@ZIF-8-DOX. Digital photo of excised tumors from sacrificed mice in 4T1 tumor-bearing
mice with different treatments. Reproduced with permission.[60] Copyright 2018, The Springer Nature.
kinds of bacteria. SEM imaging of the remaining/corpse bacte-
ria on silicon wafers confirmed the positive impact of laser treat-
ment, i.e., PDT, on biofilm eradication function of ZPM, ZPMA,
and ZPMAVP to decrease the number of adhered bacteria on the
surface. The antibacterial mechanism of the ZPMAVP NPs was
attributed to the generation of ROS by Ag+ released from the NPs
and also through the PDT. In vivo antibacterial tests were carried
out on bacterial endophthalmitis model constructed in the eyes
of New Zealand White Rabbit. Compared to the eyes treated by
Van, the symptoms of endophthalmitis in the groups treated by
ZPMAVPNPs under laser irradiation weremild and conjunctival
congestion and anterior chamber empyema were not obviously
observed (Figure 11E,F). The number of bacteria after 7 days in
the vitreous humor of the eyeball of the rabbit cultured on an agar
plate and administrated with Van and ZPMAVP/laser groups was
less than 1 × 105 and 1 × 103 CFU mL−1, respectively, while this
number in the control group was more than 1 × 1010 CFU mL−1
(Figure 11G). Collectively, the in vitro and in vivo antibacterial ex-
periments demonstrated the effect of the PDT on endophthalmi-
tis therapy, opening new ways in the PDT-mediated treatment of
eye diseases due to naturally good light transmission of the eyes.
This nanosystem not only introduced ZIF-8 as a biocompatible
carrier, but also microporous structure of ZIF-8 was reported as
a molecular cage to prevent the self-aggregation of MB as pho-
tosensitizer. Recently, this property of ZIF-8 has been used in
encapsulating hydrophobic PS squaraine (SQ) to enhance PDT
efficacy of SQ against drug-resistant planktonic bacteria and its
biofilm.[116]
4.3. Theranostics Applications of ZIF Nanocomposites
Nanotheranostic is the integration of therapeutic and diagnos-
tic modalities into a single nanosystem to achieve imaging-
guided therapy.[266] Such nanoplatforms have received a great
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Figure 11. A) Schematic preparation of ZPMAVP nanosystem and its application in combined CPDT of endophthalmitis. Bacterial viability of B) S. aureus,
C) E. coli, and D) MRSA, using plate counting methods (#p < 0.05, ##p < 0.01, ###p < 0.001, *p < 0.05, **p < 0.01, ***p < 0.001) after treatments with
ZPM NPs, ZPMA NPs, and ZPMAVP NPs. Photographs and slit lamp micrographs of endophthalmitis caused by E) S. aureus and F) MRSA at days 1,
3, and 7 after treatment with PBS, Van, and ZPMAVP+laser. G) Agar plate culturing of S. aureus and MRSA at day 7 available in the vitreous fluid after
treatment with PBS, Van, and ZPMAVP+laser NPs. The power of the laser in all the experiments was 202 mW cm−2. Reproduced with permission.[262]
Copyright 2019, Wiley-VCH.
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Figure 12. A) Schematic illustration of the construction of DOX@ZIF-HA and Fe3+-mediated coordination interaction between PDA and HA. B) DOX
release profiles of DOX@ZIF-HA under different pH conditions. C) The in vitro MR imaging ability of DOX@ZIF-HA. The linear fitting of 1/T1 as a func-
tion of Fe concentration. The inset shows corresponding T1-weighted MR images of DOX@ZIF-HA at different Fe concentrations. D) The CCK-8 assay
of PC-3 cells treated with free DOX, DOX@ZIF-HA, and DOX@ZIF-HA plus free HA at different drug concentrations. Reproduced with permission.[194]
Copyright 2018, The Royal Society of Chemistry.
promise in real-time monitoring and treating cancer and other
hard-to-treat diseases, while playing a pivotal role in the de-
velopment of personalized medicines.[266] Recently, nanoscaled
MOFs (NMOFs), including ZIFs, have emerged as one of the
most promising nanotheranostic systems due to their huge
porosity, large surface area, tunable functionality, and good
biocompatibility/biodegradability.[4,21,45,200,267–270] Single or even
multimodal imaging by ZIF-based theranostic systems has been
recently studied.[24,61,194] Herein, we discuss how these multi-
functional nanosystems work to simultaneously monitor and
treat cancer. Fluorescent carbon nanodots (C-dots) as safe imag-
ing agents, which had strong fluorescence intensity were encap-
sulated within ZIF-8 and were used as theranostic after 5-FU
loading for simultaneous pH-responsive DDS and fluorescence
imaging of cancer cells in vitro.[61] In the study, it was also shown
that, using a facile two-stepmethod, the size of the ZIF-8NPswas
tuned by changing the initial concentrations of 2-MeIm and Zn2+
ions and it was confirmed that fluorescence intensity C-dots en-
capsulated ZIF-8 was adjustable by varying the amount of C-dots.
Although there are many examples on the construction of
core−shell structures using ZIFs for theranostic applications,
these systems might suffer from complexity and high cost of
the methods. Surface modification of ZIFs is an alternative ap-
proach to incorporate imaging agents on ZIFs to make multi-
functional theranostic nanosystems.[21] Similar to the report of
Zheng et al.[100] discussed in the previous sections, Shu et al.[194]
loaded DOX into ZIF-8 through a one-pot process and then the
resultant DOX@ZIF-8 was subsequently coated with PDA. In
order to add a magnetic resonance imaging (MRI) agent, the
PDA coated DDS was successively chelated with Fe3+ and fur-
ther conjugated with HA (DOX@ZIF-8-HA) (Figure 12A). The
HA acted as targeting ligand toward the PC-3 prostate cancer cell
line, proved by confocal laser scanning microscopy and flow cy-
tometry. Innate acid degradability of ZIF-8 caused pH-responsive
release of DOX from the multifunctional DDS (Figure 12B). Fur-
thermore, the Fe3+ functioned as a contrast agent for MRI (Fig-
ure 12C). Therapeutic activity of DOX@ZIF-8-HA was assessed
using the cell counting kit-8 (CCK-8), demonstrating targeting
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ability of the nanosystem toward CD44 overexpressed PC-3 cells
and improving its intracellular uptake and enhancing its in vitro
chemotherapeutic efficacy, as compared to the free DOX. (Fig-
ure 12D). In addition, free HA had a negligible impact on the
therapeutic efficacy of DOX@ZIF-HA.
In addition to the above-explained example, diverse sin-
gle modal imaging agents, such as upconversion NPs
(UCNPs),[198,200,201] CuS NPs,[175] cobalt ferrite (CoFe2O4)
NPs,[203] cadmium sulfide (CdS) NPs,[28] and chromium-doped
zinc gallogermanate (ZGGO) NIR persistent luminescent
NPs,[204] have been employed to prepare core−shell nanoth-
eranostics after their coating by ZIFs and encapsulation of
chemotherapeutic drugs.
As a result of the high effectiveness, noninvasiveness, and
concurrent fluorescence imaging property of PDT, this method
has gained great attention to be part of theranostic systems for
cancer therapy. A PS, oxygen, and light are key components
for successful PDT.[271] However, one of the main challenges
in PDT is the self-aggregation of PSs in aqueous environments
because of its hydrophobic nature, leading to quick quenching
of PDT and poor efficiency of the systems.[272] Xu et al.[177]
utilized ZIF-8 NPs as a stabilizer to encapsulate and separate
water-insoluble photosensitizer zinc(II) phthalocyanine (ZnPc)
molecules inside nanoscale molecular cages of ZIF-8 tomaintain
the PS as monomeric in aqueous solution for efficient PDT.
The ZnPc@ZIF-8 nanosystem showed highly efficient cytotoxic
singlet oxygen generation capability and excellent photodynamic
activity towards HepG-2 cancer cells. This system also exhibited
red fluorescent emission after endocytosing by the cancer cells,
paving a way to overcome self-aggregation/bioavailability prob-
lems of PSs for imaging-guided PDT. It should be noted that the
self-aggregation of PSs and hypoxia at the tumor sites are the
main limitations in the development of cancer PDT methods.
As a result of the degradation of manganese oxides (MnO2)
into Mn2+ ions in an acid solution of H2O2, such chemistry can
boost the concentration of O2 in TME, therefore increasing the
efficiency of PDT process.[273–275] In addition, released Mn2+
ions were exploited as contrast agent for MRI. Utilizing the
nanoenzyme-like/O2-generating behavior of MnO2, BSA-MnO2
NPs were loaded onto the surface of Ce6, a hydrophobic pho-
tosensitizer, encapsulated-ZIF-8 (BSA-MnO2/Ce6@ZIF-8) NPs
for MRI-guided PDT of cancer (Figure 13A).[276] The successful
synthesis of BSA-MnO2/Ce6@ZIF-8 was confirmed by TEM,
dynamic light scattering (DLS) and energy-dispersive X-ray
spectroscopy (EDS) (Figure 13B–D). For example, EDS revealed
the presence of O, N, Zn, S, and Mn, proving the existence of
BSA-MnO2 NPs on the surface of Ce6@ZIF-8 NPs (Figure 13C).
As shown in Figure 13E, BSA-MnO2/Ce6@ZIF-8 NPs were able
to producemore oxygen at pH 5.0 than the pH 7.4. Such behavior
was attributed to the simultaneous presence of H+ and H2O2
that triggered the catalase-like activity of nanosystem, confirm-
ing the O2-generating capability of the BSA-MnO2/Ce6@ZIF-8
NPs to relieve hypoxia in cancer therapy using PDT meth-
ods. Both cell viability and in vivo tumor growth inhibition
studies confirmed the outstanding killing effect derived from
the PDT under 650 nm NIR laser irradiation (Figure 13F–
H). Moreover, MRI after injection of the NPs proved that the
BSAMnO2/Ce6@ZIF-8 could effectively accumulate in the tu-
mor sites, holding great promise in MRI-guided cancer therapy
(Figure 13I).[276]
Visible-light photosensitizer graphitic carbon nitride (g-C3N4)
nanosheets, as a photodynamic therapeutic agent, were en-
capsulated within ZIF-8 by growing ZIF-8 components in the
presence of g-C3N4 nanosheets.
[180] Chemo-photo combination
therapy was conducted by DOX-loaded g-C3N4@ZIF-8 NPs,
generating singlet oxygen for PDT and delivering DOX with a
pH-sensitive manner for chemotherapy. Blue fluorescence of g-
C3N4 nanosheets and red fluorescence of DOX rendered nanoth-
eranostic property to the particles due to the combined imaging-
guided chemo/phototherapy of cancer cells.
It is important to consider that sufficient interaction between
ZIF-8 and drugs is essential to achieve high drug encapsulation
through ship-in-bottle approaches, i.e., concurrent drug load-
ing and ZIF construction. However, only drugs containing polar
functional groups (PFG), e.g. carboxylic acid, carbonyl, and sul-
fonic groups, have shown satisfactory results in the loading step.
Therefore, drug molecules without these functional groups need
to be functionalized with appropriate PFGs to reach acceptable
drug loading. Zhang et al.[187] developed a versatile prodrug strat-
egy, using cytarabine as a model drug that had insufficient load-
ing in ZIF-8, and was covalently attached with new indocyanine
green (IR820), containing sulfonic groups to produce a prodrug
via an amide linkage. Sulfonic groups of prodrugs coordinated
with the zinc ions in ZIF-8-IR820, strengthening the interaction
of prodrug with ZIF-8, thereby resulting in a high drug loading
content of 39.8%. Importantly, due to light to heat conversion ca-
pability and fluorescence emission capability of IR820, the de-
veloped DDS, after functionalizing with HA as targeting ligand,
was successfully applied in fluorescence imaging-guided CPTT
in vitro breast cancer.
Although single-modality therapies, i.e., chemotherapy, PTT,
or PDT, have attracted much attention in cancer therapy, each
modality has its own disadvantages, which force the usage of
multi-therapies to induce a synergistic effect.[1] The combina-
tion of chemotherapy, PDT, PTT, and immunotherapy by ZIF-
8 as a nanomedicine platform was developed by Yang et al.[24]
(Figure 14). DOX, CuS NPs, and protoporphyrin IX (PpIX)
used as chemotherapy, PTT, and PDT agent, respectively, were
loaded within ZIF-8. The CuS NPs not only served as PTT
agent to convert light (808 nm) to heat, but also accelerated
DOX release under NIR irradiation. The resulting DOX-CuS-
PpIX@ZIF-8 was coated by unmethylated cytosine phosphate-
guanine (CpG) oligonucleotide as immune adjuvant through
electrostatic interaction for immunotherapy with the aim of pre-
venting cancer metastasis/recurrence. To realize MR imaging,
MnO2 nanosheets were grown on the CpG coated NPs after sur-
face modification of the NPs by the PDA layer. The PDA acted
as a gatekeeper to prevent the drug leakage before reaching to
cancer sites and enhanced the PTT effect. Therefore, an “all-in-
one” nanotheranostic was successfully utilized for MRI-guided
chemo/photothermal/photodynamic/immunotherapy of cancer
with anti-metastasis/recurrence property. This example clearly
demonstrated how the interior and exterior surfaces of ZIF-8 can
truly be exploited to construct multifunctional nanocomposites
intended for concurrent diagnosis and multi-modal therapy.
One of the main advantages of multifunctional NPs is multi-
modal imaging, enabling them to combine two or more imag-
ing modalities for simultaneous imaging and therapy. As each
imaging modality has its own intrinsic limitations, therefore
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Figure 13. A) Schematic illustration of BSA-MnO2/Ce6@ZIF-8 synthesis and nanoenzyme-like behavior of the nanosystem upon irradiation with 650 nm
NIR laser intended for MRI-guided PDT of cancer. B) TEM and C) EDS images of BSA-MnO2/Ce6@ZIF-8 NPs. D) Zeta-potential measurements of ZIF-8,
Ce6@ZIF-8, BSA-MnO2, and BSA-MnO2/Ce6@ZIF-8. Insets are the corresponding photographic images of bare ZIF-8 NPs 1), Ce6@ZIF-8 NPs 2), and
BSA-MnO2/Ce6@ZIF-8 NPs 3). E) Oxygen generation by the Ce6@ZIF-8 NPs and BSA-MnO2/Ce6@ZIF-8 NPs in the presence of H2O2 at different pH
values of 7.4 and 5. F) Viability of HeLa cells after incubation with different concentration of BSA-MnO2/Ce6@ZIF-8 under 650 nm laser irradiation. G)
Time-dependent tumor growth curves in tumor-bearing mice treated differently. H) The representative photographic images of tumor tissue in tumor-
bearing mice after the different treatments. I) In vivo T1- and T2-weighted MRI before and after injection with the BSA-MnO2/Ce6@ZIF-8 nanoplatform.
Reproduced with permission.[276] Copyright 2019, American Chemical Society.
the integration of several imaging agents within a single sys-
tem may allow more accurate diagnosis of diseases through.[1]
For the first time, the intrinsic two-photon fluorescence imag-
ing property of ZIF-8 NPs derived from 2-MeIm was reported
by Zhao et al.[182] Such an intrinsic property holds great po-
tential for the fabrication of novel theranostic platforms. In-
spired by the excellent advantages of ZIF-8 in the constriction
of multifunctional NPs, Bian et al.[23] prepared an “all-in-one”
imaging system, i.e., Fe3O4@PAA/AuNCs/ZIF-8, integrating tri-
modal imaging of MRI, CT, and optical imaging (OI), where
Fe3O4 and AuNCs acted as MRI and CT/OI agents, respectively.
To prepare the nanocomposite, oleic acid (OA) capped Fe3O4
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Figure 14. A) Schematic depiction of preparing “all-in-one” nanocomposite of DOX-CuS-PpIX@ZIF-8-PDA-MnO2. B) Theranostic property of
the nanocomposite for MRI-guided chemo/photothermal/photodynamic/immunotherapy to eliminate the primary solid tumor. Reproduced with
permission.[24] Copyright 2018, The Royal Society of Chemistry.
NPs were firstly modified by CTAB surfactant. After the coat-
ing of the CTAB-functionalized NPs by PAA molecules, the
Fe3O4@PAA core–shell NPs were obtained. Subsequently, the
resultant Fe3O4@PAA NPs were incorporated by glutathione
capped AuNCs to form Fe3O4@PAA/AuNC NPs. Finally, the
Fe3O4@PAA/AuNCs/ZIF-8 nanocomposite was prepared by the
addition of Zn2+ and 2-MeIm. The nanocomposite showed ul-
trahigh DOX loading (1.54 mg DOX per 1 mg of NPs) and high
magnetic property. In addition, the NPs showed low systematic
toxicity in vivo and suppressed the tumor growth effectively by
DOX delivery into the tumor tissue of Balb/c mice through in-
travenous injection. DOX-loaded Fe3O4@carbon@ZIF-8 multi-
functional nanotheranostics were also fabricated by He et al.[202]
for pH-triggered release of DOX in vitro. The superparamagnetic
iron oxide nanocrystals and carbon dots acted as MR and fluo-
rescence imaging contrast agents, respectively. In addition, the
remarkable inhibition of tumor growth without side effects was
obtained in vivo in the A549 lung cancer mice model after intra-
venous injection.
As mentioned in the previous sections, one of the main obsta-
cles of cancer CDT is the insufficient concentration of H2O2 in
TME, leading to the poor performance of this technique.[221] Ar-
tificial in situ generation of H2O2 in TME, for example, through
the conversion of 𝛽-d-glucose to gluconic acid and H2O2 by GOx,
is a reliable way to overcome the shortcomings of CDT.[221] In
2018, Zhang et al.[277] developed an ATP-responsive autocatalytic
Fenton nanosystem, called GOx@ZIF@MPN, by the incorporat-
ing of GOx in ZIF-8, and then, coating the whole system with
Fe(III)/TA polyphenol network (MPN) for suppressing tumor
growth mediated by enhanced chemodynamic-starvation ther-
apy (Figure 15A,B). As a result of the ATP upregulation in tu-
mor cells, as compared to normal cells, and potential degrada-
tion of Fe(III)/TA MPNs in overproduced ATP environments,
the MPN shell of the designated nanosystem was degraded into
Fe(III) and TA in tumor cells while the internal GOxwas exposed.
Afterwards, GOx was reacted with the endogenous glucose to
generate sufficient H2O2 for CDT, while TA as reducing agent
converted Fe(III) to Fe(II) to further push forward the Fenton re-
action to generate highly toxic hydroxyl radical (•OH) by Fe(II)
as a catalyst. It should be noted that TA played a crucial role
in accelerating Fe(III)/Fe(II) conversion to guarantee highly ef-
ficient Fenton reaction mediated CDT. ATP-responsive degrada-
tion of GOx@ZIF@MPN was shown by the release of iron at
different ATP concentrations (Figure 15C). The iron release was
increased when ATP concentration and treating time increased,
demonstrating the ATP-responsive property of the nanosystem,
due to the strong binding affinity of ATP to Fe(III). After intra-
venous injection of Cy5.5-loaded GOx@ZIF@MPN NPs to 4T1
tumor-bearingmice, the fluorescence intensity was gradually en-
hanced over time and then weakened, but still retained in a de-
sirable level after 24 h, confirming long time blood circulation of
the NPs (Figure 15D). In addition, the MRI signal was detected
after 10 min of the post-injection due to the T1-weighted con-
trast effect of GOx@ZIF@MPN after intratumoral injection. The
MRI signal was gradually enhanced over time till 30min, demon-
strating rapid degradation of the MPN shell in response to ATP
at the tumor site and generation of excellent T1-weighted imag-
ing signal for tumor diagnosis (Figure 15E). As shown in Fig-
ure 15F,G, studies on 4T1 cells treated with GOx@ZIF@MPN
showed that the nanosystem had very high toxicity against the
cancer cells both in vitro and in vivo, when compared to control
groups of GOx@ZIF and ZIF@MPN, confirming a synergistic
effect of CDT and starvation therapy on the cancer ablation. Such
an enhanced therapeutic effect was also observed by the photo-
graphic imaging of harvested tumors from each treatment group
after sacrificing mice (Figure 15G). Very recently, a biomimetic
cascade nanoreactor based on ZIFs, i.e., DOX-loaded GOx@ZIF
camouflaged by the tumor cellmembrane, was also developed for
synergistic chemotherapy and starvation therapy.[125] Indeed, the
biomimetic membrane endowed the NPs with superior immune
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Figure 15. A) Schematic representation of GOx@ZIF@MPN synthesis as an ATP-responsive nanotheranostic for Fenton reaction mediated CDT and
detailed description of glucose consumption, H2O2 generation and Fe(III) to Fe(II) conversion processes. B) The TEM image of GOx@ZIF@MPNNPs.
C) Fe(III) release from GOx@ZIF@MPN at different ATP concentration levels. D) In vivo fluorescence images of tumor-bearing mice after intravenous
injection of Cy5.5-doped GOx@ZIF@MPN NPs at various times. E) T1-weighted MRI images after intratumoral injection of GOx@ZIF@MPN NPs at
various times. F) In vitro viability of 4T1 cells after incubating with different samples in the presence of glucose. G) Tumor volume growth curve of
mice in different groups and photographic images of 4T1 tumor tissues in different groups after 14 days of treatment. Reproduced with permission.[277]
Copyright 2018, American Chemical Society.
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Figure 16. A) Schematic illustration of the Au@MOF-DOX synthesis and its imaging and synergistic anticancer property. B) TEM images Au@MOF
and C) yolk-shell structural Au@MOF. D) The heating and cooling curves of Au@MOF (200 ppm of Au) irradiated at 1064 nmNIR laser. E) Temperature
change profile of Au@MOF with different concentrations of Au and F) the profile at various power densities for 10 min with 50 ppm of Au concentration
exposed to 1064 nm NIR laser. G) In vivo ITI images of H22 tumor-bearing mice. The mice were intravenously injected with PBS or Au@MOF NPs
irradiated with 0.8 W cm−2 1064 nm laser for 5 min. H) In vivo PAI images of Balb/c nude mice. The mice were intravenously injected with Au@MOF
NPs. I) Time-dependent tumor growth curves of tumor-bearing mice in different groups. Reproduced with permission.[282] Copyright 2019, American
Chemical Society.
evasion and homologous targeting capacities, thereby introduc-
ing a novel and efficient method for precise tumor therapy.
Yolk–shell nanocomposites (YSCs), integrating different com-
positions and functionalities in a single system have attracted
wide attention in biological research.[278,279] In fact, the hollow
cavity of the YSCs can act as a container for loading more car-
gos and the shell can serve as a protective layer for the yolk,
which can be made of a wide variety of NPs.[280,281] Recently, an
interesting multifunctional YSC was constructed by integrating
star-shaped gold (Au star) NPs and ZIF-8 as the shell[282] (Fig-
ure 16A). As a result of the acid-degradability of ZIF-8 NPs, the
part of the ZIF-shell was selectively removed by TA as an etchant
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Scheme 2. Schematic illustration of the facing challenges and future progresses of ZIF-based nanostructures for biomedical applications.
to obtain the yolk-shell structures (Au@MOF) (Figure 16B,C).
The yolk-shell Au@MOF nanocomposite not only worked as a
photothermal agent at NIR-I (750–1000 nm), but also showed
very high photothermal transformation efficiency at NIR-II re-
gion (1000–1700 nm; Figure 16D–F), which is of particular im-
portance in deeper tissue penetration and higher spatiotemporal
resolution than NIR-I region. Moreover, due to the strong NIR
light absorbance of the Au yolk, the nanosystem was able to be
used for ITI and PAI of cancer tissue (Figure 16G,H). After DOX
encapsulation and upon the laser irradiation at NIR-II window
(1064 nm), the Au@MOF exhibited outstanding synergistic tu-
mor ablation effect based on the light to heat conversion prop-
erty of the Au yolks and anti-cancer property of DOX (Figure 16I),
which caused a remarkable synergistic anticancer effect through
combined chemo-phototherapy.
5. Conclusions
Recently, the scientific community has witnessed the consider-
able achievements of ZIFs for versatile biomedical applications,
especially in the stimuli-responsive DDSs and biomineralization
of elegant bio-macromolecules due to their unique features, in-
cluding tunable pore size, large surface area, high thermal stabil-
ity, and favorable biodegradability/biocompatibility. Herein, we
have comprehensively discussed the very recent developments
for the controlling of the physicochemical properties of ZIFs and
their impact on diverse cargo loading and the release trend of
various molecules, including drugs, bio-macromolecules, photo-
sensitizers, and photothermal agents, in order to produce opti-
mized DDSs for the treatment of different diseases, such as can-
cer and infection. Although the study of biomedical applications
of ZIFs is in its infancy phase, it has opened promising and in-
triguing prospects based on their high performance in many ap-
plications, which was discussed in this review paper (Tables 1
and 2). However, despite the growing interest and impressive
advancements in this field, some critical issues and foreseeable
challenges are crucial to be considered and addressed for the ra-
tional design of ZIF-based nanosystems for versatile biomedical
applications (Scheme 2). First, broadening the biomedical appli-
cations of ZIFs and improving the therapeutic efficacy of its de-
rived nanomedicines should be further investigated. The intrin-
sic characteristics of ZIFs endow themwith superior capability in
the loading of different cargos in a single particle to exploit them
as multifunctional carriers. For example, in the case of cancer
therapy or bacterial infection, efficient boosting of the therapeu-
tic efficacy might be achieved by the integration of immunother-
apeutic and starvation agents with chemo and phototherapeutic
cargos to increase the efficacy of the ZIF nanosystems. While
the current advancements on the of the ZIFs have focused on
the abovementioned diseases, other biomedical applications, in-
cluding biosensing, brain disease therapy, tissue engineering, in-
flammation alleviation, etc., are yet to be investigated. In addi-
tion, the synthesis of other novel and multifunctional derivatives
of ZIF NPs rather than ZIF-8 might expand the applications of
the porous ZIF-based nanomaterials in nanomedicine. In this
context, the physicochemical properties of ZIFs, including parti-
cle size, pore size, surface modification/targeting, compositional
andmorphological featuresmust be carefully tuned tomeet stan-
dard requirements for in vivo studies.
The second issue is related to the large scale preparation of
ZIFs with adjustable particle diameter and pore size and the
exploration of new targeting ligands for surface modification
of the ZIFs. This issue can affect the drug loading into the
ZIFs, alter drug accumulation at a specific site, and markedly re-
duce/increase the uptake of the NPs by RES organs. At present,
ZIFs are mainly prepared in a lab-scale and researchers must
work on the development of synthesis approaches for the rapid
and reproducible production of these nanomaterials in a large
scale. Since the toxicity and poor loading are the main concerns
for the bench to bedside movement, preparation of HZIFs can be
suggested as an alternative to enhance the drug loading efficiency
and reduce the frequency of administration, thus overcoming the
toxicity concerns of ZIF carriers.
At present, due to the novelty of ZIFs and limited understand-
ing of their biological effects, most of the research is towards
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developing “proof-of-concept” studies that are not clinically rele-
vant. For future clinical translation, short and long-term biosafety
on different organs, biodegradability, biodistribution, blood half-
life, and clearance of the ZIFs must be studied comprehensively.
Such studies should be conducted not only in small animals,
such as rabbit andmouse, but also in big animals, including pigs
and dogs to produce clinically applicable ZIF-based nanoscale
formulations. To this end, we do believe that the physicochemical
properties of ZIFs are essential factors that should be optimized
to push forward these nanosystems for clinical application.More-
over, since the interaction of ZIFs with the immune system has
remained largely unknown, the influence of these NPs with im-
mune cells should be clarified before developing new techniques
for their large scale production.
Taken all together, the engineering of ZIFs for biomedical ap-
plications is still in an infancy stage and there are plenty of op-
portunities to design and fabricate advanced DDSs in this bur-
geoning field of nanomedicine. To achieve this goal, closer and
strengthened collaboration among experts from diverse fields
will highly be imperative if we expect novel clinical innovations
and personalized medicine in the near future through revealed
therapeutic and diagnostic mechanisms of ZIF-based “magic
bullet.”
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